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Abstract 
Recurrent pregnancy loss (RPL) and recurrent implantation failure (RIF) are major barriers 
to wanted pregnancies. Currently, there are few tests that reliably predict pregnancy 
outcome in these groups.  Recent research demonstrated that an aetiological factor in early 
reproductive failure is impaired endometrial decidualisation due to accelerated senescence 
and loss of endometrial mesenchymal stem cells. Uterine Natural Killer (uNK) cells maintain 
homeostasis by clearing senescent decidual cells. I aimed to improve the ability of the uNK 
cell density test in predicting subsequent pregnancy outcomes, through a combined pre-
conceptual test that includes cell senescence and proliferation markers. 
Methods 
This study was performed in a tertiary research ‘Implantation Clinic’, where the uNK cell 
density test is performed on mid-luteal endometrial biopsies in women with RPL and RIF. I 
began my investigation of a predictive test by assessing the predictive ability of the uNK test 
using the clinic’s large retrospective database (N=281). 
Next, immunohistochemistry was performed on endometrial serial sections of women with 
RPL using antibodies to CD56 (uNK), Ki67 (cell proliferation), HMGB2 and p16 (cell 
senescence) via an automated staining process. The images were analysed using 
Pannoramic Viewer and Image J software with colour de-convolution and thresholding 
technique. The findings of the exploratory test set (N=20) were used to develop a pre-
conceptual combined test for outcome prediction in a larger study (N=89). 
Final validation of the combined test ‘uNK-glandular p16’ was conducted on samples from 
women with RPL recruited in the setting of a prospective, randomised-controlled trial (RCT). 
Results 
Combining the normalised uNK and glandular p16 results improved the prediction of 
pregnancy outcome (p=0.0163). The predictive ability of the combined test ‘uNK-glandular 
p16 centile’ was validated in the prospective RCT setting. 
Conclusion 
Glandular-stromal synchrony appears to be an important determinate of pregnancy 
outcome and may help focus future research or therapy. 
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Chapter 1: Introduction 
1.1 Recurrent reproductive failure 
Recurrent reproductive failure in the context of this thesis, encompasses recurrent 
pregnancy loss (RPL) and recurrent implantation failure (RIF). Recurrent 
reproductive failure causes considerable distress to couples wanting to have a 
family. Understanding the complex processes involved in human reproduction is 
crucial in the effort to improve pregnancy outcomes for these couples. At present 
there are numerous investigations and therapies offered to couples suffering 
recurrent reproductive failure. Couples will invest significant time, money and take 
on a level of health risk in order to achieve successful childbirth, even on treatments 
with low success rates.  Many of the treatments offered to couples do not have 
strong evidence of a positive effect on pregnancy outcomes. Hence further research 
in this area is badly needed. 
In the next few chapters, I discuss human reproduction, recurrent pregnancy loss 
and recurrent implantation failure in further detail. 
 
1.1.1 Human reproduction 
1.1.1.1 Fertilisation 
Human reproduction is dependent on a viable ovum, sperm and ability of both 
gametes to meet in the Fallopian tube to fertilise, unless assisted reproductive 
technology is used. Fertilisation of the ovum usually occurs in the ampulla of the 
Fallopian tube. The process of fertilisation begins with chemoattraction of the sperm 
to ovum and adherence to the zona pellucida surrounding the ovum (Bahat et al., 
2003).  
Spermatozoa with active movement, particularly progressive motility comes into 
close contact with the ovum (secondary oocyte arrested at metaphase of Meiosis II). 
The acrosome reaction releases enzymes, in particular hyaluronidase, that enables 
penetration of the zona pellucida by spermatozoa (Holt & Van Look, 2004). The 
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sperm head adheres to the cell membrane of the ovum with breakdown of the area 
of fusion and release of the spermatozoon nucleus into the cytoplasm of the ovum. 
As the spermatozoon binds to the cell membrane of the ovum, the membrane 
becomes impenetrable to other spermatozoa. The successful spermatozoon is 
engulfed by the ovum’s cytoplasm. The sperm head then converts into the male 
pronucleus and the tail detaches. Alongside this, the ovum completes meiosis II 
creating a female pronucleus (Ganong, 2003). Both pronuclei meet and resolve into 
one nucleus with a complete set of 23 chromosomes creating a zygote, which 
contains all essential factors to develop into a new individual. The embryonic period 
begins with the first division of the zygote after 24 hours of fusion. 
The fertilised ovum then travels down the tube to the uterus in about 3 days. In this 
time, the conceptus cleaves until it becomes a morula (cluster of 8 blastomeres) and 
then transforms into a blastocyst (Ganong, 2003). Between day 6 to 10 after LH 
surge, the blastocyst will enter the implantation process with the endometrium and 
be supported for 9 months in a successful pregnancy.  
 
1.1.1.2 Implantation 
 
Implantation is the stage of pregnancy where the embryo adheres to and is 
embedded into the endometrium (Coughlan et al., 2014). The conceptus is a 
blastocyst at this stage of development. The implantation window describes the 
endometrial receptive phase where interaction between embryo and maternal 
endometrium occurs (Gellersen & Brosens, 2014). Most sources state that the 
implantation window spans from day 7 to 9 post LH surge but there are reports that 
the window is wider at days 6 to 10 post LH surge (Achache & Revel, 2006; Bergh & 
Navot, 1992; Fanchin, 2001; Xiao et al., 2010). The endometrium undergoes 
decidualisation in preparation for implantation. The embryonic and maternal 
preparation for pregnancy needs to occur in tandem to support a pregnancy 
successfully (Cha et al., 2012; Gellersen & Brosens, 2014; Su & Fazleabas, 2015).  
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The process of implantation is commonly associated with a step-wise process. It 
involves apposition and adhesion of the blastocyst to the endometrium (Fazleabas 
& Kim, 2003; Genbacev et al., 2003). Following this, the blastocyst breaches the 
luminal epithelium and decidualising stromal cells migrate and surround the 
invading embryo (Dey et al., 2004; Quenby & Brosens, 2013). The migration of 
decidual stromal cells has been recorded using time-lapse imaging and in migration 
assays (Gellersen et al., 2013; Grewal et al., 2010; Grewal et al., 2008; Schwenke et 
al., 2013). This supports evidence that the endometrium plays an active role in 
reproductive success. 
There are 5 key events that are discussed in the implantation process and adopted 
by the team at Warwick (Lucas et al., 2013).  
 Positioning of embryo near fundus 
 Apposition 
The two processes above occur closely together. This multi-faceted process involves 
the embryo finding a location to implant with a position near the fundus (Chen et 
al., 2013; Salamonsen et al., 2016). At this stage, an embryo can be flushed out as it 
is not yet adherent to endometrial luminal epithelium. 
 Adhesion/attachment 
The embryo initiates direct contact between trophoblast cells and endometrial 
luminal epithelium. This occurs via apical cell membranes of the endometrium 
(Lindenberg, 1991). The inner cell mass migrates to face the trophoblast on the side 
of apposition and the adhesion process is mediated by receptor-ligand interactions 
(Salamonsen et al., 2016; Su & Fazleabas, 2015). A micro-environment is created by 
the cross-talk between the endometrium and embryo in order to support 
implantation. 
 Penetration through luminal epithelium 
At this stage, the decidual stromal cells migrate to encapsulate the implanting 
blastocyst (Quenby & Brosens, 2013). During this stage, the endometrium plays a 
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role as an embryo sensor. The endometrium is able to discriminate between high- 
and low- quality embryos (Salker et al., 2010). The decidualised stromal cells have 
been shown not to migrate towards low quality embryos and stop implantation 
(Brosens et al., 2014; Macklon & Brosens, 2014; Singh et al., 2010; Weimar et al., 
2012). 
 Invasion of stroma 
Trophoblast penetrate the endometrial epithelial layer and reach the basement 
membrane via intercellular gaps between neighbouring epithelial cells without 
destroying them (Carson et al., 2000). This is to ensure the embryo successfully 
embed in the maternal endometrium to create a haemochorial placenta. 
 
Alongside the above process, decidualisation of the endometrium occurs. The 
decidualisation process starts after ovulation and involves differentiation of 
endometrial stromal cells, blood vessels, glands and an increase in endometrial 
leucocytes. The interaction between a competent embryo and endometrium 
initiates changes that make the endometrium more receptive and enhances 
decidualisation. A receptive, decidualised endometrium allows embryo invasion and 
encapsulation by decidualised endometrial stromal cells. The process of 
decidualisation underpins embryo selection at implantation or embryo loss at 
menstruation. I will expand on these processes next. 
Decidualisation 
Decidualisation occurs in response to the actions of progesterone. Progesterone 
nuclear receptors are highly expressed in stromal cells throughout the menstrual 
cycle and pregnancy (Chen et al., 2009). Decidualisation of stromal cells is the 
differentiation of elongated fibroblast-like mesenchymal cells in the endometrial 
stroma to round epithelioid-like cells during the luteal phase of the menstrual cycle 
(Su & Fazleabas, 2015). This begins with endometrial stromal cells surrounding spiral 
arteries in the upper two-third of the endometrium, which is called pre- 
decidualization (Su & Fazleabas, 2015). This reaction persists with implantation and 
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spreads beyond the perivascular regions. Decidual stromal cells can migrate and are 
secretory; and its major secretory products are prolactin and insulin-like growth 
factor binding protein-1 (IGFB-1) (Gellersen et al., 2007).  
Endometrial response to blastocyst signals 
Human chorionic gonadotrophin (HCG) is the major signalling hormone of the 
embryo. It is a glycoprotein hormone synthesized by trophoblast cells and acts as a 
LH super agonist. It extends lifespan of the corpus luteum to support pregnancy until 
placental progesterone is produced at around 6 to 8 weeks gestation (Hallast et al., 
2005; Talmadge et al., 1983). HCG also exerts an endometrial epithelial response by 
inducing cyclooxygenase-2 (COX-2) and prostaglandin E synthase, which both 
control synthesis of prostaglandin E2 (PGE2) (Banerjee et al., 2009). PGE2 induces 
cAMP and endometrial stromal cells to promote pre- decidualization during the 
luteal phase (Tanaka et al., 1993).  
Embryo invasion and encapsulation 
The above cascade initiates endometrial stromal decidualisation and remodelling of 
stromal cell cytoskeleton. These decidualised stromal cells are intrinsically motile 
and have invasive capability (Weimar et al., 2013). This characteristic allows the 
stromal cells to encapsulate the implanting blastocyst and this has been revealed on 
time-lapse recording (Grewal et al., 2010; Grewal et al., 2008). Stromal cell 
decidualisation and motility are essential for establishment of a successful 
pregnancy (Afshar et al., 2012; Su & Fazleabas, 2015). 
Embryo selection, rejection and menstruation 
The endometrial response described serves as a biosensor of embryos. The response 
will either support the embryo or facilitate early rejection and menstruation 
(Brosens et al., 2014; Teklenburg et al., 2010). Decidualised stromal cells can sense 
poor quality embryos and will migrate towards high quality embryo and not poor-
quality embryos (Teklenburg et al., 2010; Weimar et al., 2012). This selection process 
limits maternal investment in invasive but developmentally compromised human 
embryos (Gellersen & Brosens, 2014). In the absence of implantation or in response 
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to a compromised embryo, endometrial stromal cells can trigger tissue destruction 
which also occurs due to fall in progesterone levels causing menstruation (Leitao et 
al., 2010; Leitao et al., 2011).  
Embryo nutrition 
Up to 10 weeks gestation the embryonic nutrition is from glandular secretion and 
passive diffusion (Burton et al., 2002; Salamonsen et al., 2016). This is because 
invading trophoblast cells plug the mouths of the maternal spiral arteries in the first 
10 weeks of gestation (Burton et al., 1999). Blood flow is first seen in the intervillous 
space after this time.  The initiation of blood flow into the intervillous spaces causes 
oxidative stress and is a second test of embryo fitness.  
The importance of this separation between maternal circulation and embryo is to 
provide a stable, low oxygen environment during organogenesis. This critical need is 
to reduce risk of teratogenesis related to oxygen free radicals. Once blood flow is 
initiated, nutrition occurs by exchange between maternal and fetal circulations 
within the placenta. 
 
 
1.1.2 Recurrent pregnancy loss 
 
Recurrent pregnancy loss (RPL) causes repeated physical and psychological trauma 
for the couple involved (Craig et al., 2002b). In the United Kingdom, recurrent 
pregnancy loss is defined as 3 or more consecutive miscarriages of pregnancies 
under 24 weeks gestation. This affects 1-2% of couples trying to conceive (Rai & 
Regan, 2006). However, in other countries, for example The Netherlands and North 
America, recurrent miscarriage is defined as 2 consecutive miscarriages. This latter 
definition has been adopted by the European Society of Human Reproduction and 
Embryology (ESHRE) in their RPL guidance. Unfortunately, management of these 
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couples is fraught with controversy and at times influenced by personal bias and 
small uncontrolled studies.  
Numerous causes have been invoked to explain recurrent pregnancy loss but many 
are unsubstantiated (Barber et al., 2010). In practice, therapies such as low 
molecular weight heparin (LMWH) thromboprophylaxis (Kaandorp et al., 2010; 
Laskin et al., 2009; Visser et al., 2011) and immunomodulators (Ata et al., 2011; 
Stephenson et al., 2010) are frequently used despite current paucity of evidence 
that these approaches are effective.  
Dedicated recurrent pregnancy loss clinics should aim to offer couples support in 
early pregnancy and where possible, within a monitored research setting. The 
research aim is to identify underlying causes, conduct prospective randomised 
controlled trials (RCT) of sufficient power and determine best treatment regimens.  
This set up could still be delivered in general district hospitals with input from 
tertiary centres. An ideal, well-orchestrated service is one that can offer early 
pregnancy reassurance scans, availability of cytogenetic testing and is research 
active in a multi-centre setting. Counselling services similar to those offered to 
fertility patients could be beneficial and considered in the holistic care of a select 
number of affected couples. Currently, care and services available to RPL couples 
are not uniform throughout the United Kingdom.  
Underpinning the controversy of effective therapy is the fact that the 
pathophysiology of RPL remains unclear. One of the many difficulties in ascertaining 
the pathophysiology and cause of RPL is the heterogeneity of this study population.  
Most miscarriages are a process of natural embryo selection and are sporadic 
pregnancy losses with abnormal karyotype that are not compatible with life. 
However, as the number of miscarriages increases so does the chance of miscarriage 
of a normal embryo, thereby increasing the chance of a maternal preventable 
pathology (Lund et al., 2012; Ogasawara et al., 2000) (Figure 1.2). This change in 
odds appears to occur after 5 miscarriages (Figure 1.3).  
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For patients and clinicians, it is unacceptable to delay investigations until couples 
experience 5 miscarriages. Therefore, it is essential to identify women who have an 
underlying pathology at an earlier stage to individualise management and predict 
outcome of subsequent pregnancies. 
Although the background chance of live birth is good following 3 miscarriages, all 
couples suffer anxiety and need support in early pregnancy. To illustrate, a woman 
age 30 to 35 years with a history of 3 miscarriages has a successful pregnancy rate 
of 70-80% (Brigham et al., 1999; Ogasawara et al., 2000).  New tests and treatments 
are needed at this stage, to identify and if possible, prevent the 20-30% who will 
have a repeated pregnancy loss of a normal embryo. 
 
 
 
Figure 1. 1: Karyotype of miscarriages in relation to number of previous miscarriages. 
Reprinted from Fertility Sterility, 73(2); Ogasawara, M., Aoki, K., Okada, S. & Suzumori, K. (2000) Embryonic 
karyotype of abortuses in relation to the number of previous miscarriages. Fertil Steril, 73 (2): 300-304, with 
permission from Elsevier 
As shown in this figure, the presence of karyotypically abnormal fetuses is high in 
subsequent miscarriages for women with history of 2 to 4 miscarriages. Their successful 
pregnancy rates are reassuringly high. However, as the number of previous miscarriages 
reaches 5, the chances of miscarrying a normal embryo rises exponentially. It is the loss of 
these pregnancies that we need to implement measures to prevent. 
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Figure 1. 2: RPL and prognosis for live birth (number of miscarriages). Reprinted with permission 
from Obstet Gynecol; Lund, M., Kamper-Jorgensen, M., Nielsen, H. S., Lidegaard, O., Andersen, A. M. & 
Christiansen, O. B. (2012) Prognosis for live birth in women with recurrent miscarriage: what is the best 
measure of success? Obstet Gynecol, 119 (1): 37-43 
https://journals.lww.com/greenjournal/fulltext/2012/01000/Prognosis_for_Live_Birth_in_Women_With_Recur
rent.7.aspx  
This figure is a Kaplan-Meier plot showing the percentage of women with RPL who have 
had at least one live birth after their first consultation and are grouped by the number of 
previous miscarriages. Successful pregnancy rates begin to decline significantly following 5 
or more previous miscarriages. These findings support those shown in the previous graph 
(Figure 1.2). 
 
In initial consultation with couples, the risk factors and modifiable behaviours should 
be discussed. The recently published ESHRE Recurrent Pregnancy Loss guidance in 
November 2017, is a comprehensive clinical practice guideline formed after careful 
consideration of the scientific evidence available and provides an aid to healthcare 
professionals in clinical decisions about appropriate and effective care for their 
patients (Bender Atik et al., 2018). I will now discuss the risk factors, modifiable 
behaviour and investigations in RPL. 
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1. Risk factors 
The main prognostic risk factors are age and number of previous miscarriages.  
Age 
Advanced female age is a risk for recurrent pregnancy loss, subfertility and obstetric 
complications (Nybo et al., 2000; Sauer, 2015). It was found that female age ≥ 35 
years doubles the risk of another pregnancy loss compared to younger women (OR 
1.99; 95% CI 1.45-2.73) (Lo et al., 2012). Risk of RPL increases dramatically from age 
40 as demonstrated in a 5-year follow up cohort study of 987 couples (Lund et al., 
2012) (Figure 1.4).  
 
Figure 1. 3: Recurrent miscarriage and prognosis for live birth (maternal age). Reprinted with 
permission from Obstet Gynecol; Lund, M., Kamper-Jorgensen, M., Nielsen, H. S., Lidegaard, O., Andersen, A. M. 
& Christiansen, O. B. (2012) Prognosis for live birth in women with recurrent miscarriage: what is the best 
measure of success? Obstet Gynecol, 119 (1): 37-43 
https://journals.lww.com/greenjournal/fulltext/2012/01000/Prognosis_for_Live_Birth_in_Women_With_Recur
rent.7.aspx 
This is a Kaplan-Meier plot showing the percentage of women with recurrent miscarriage 
who have had at least one live birth after first consultation and are grouped by age. This 
emphasises the impact maternal age has on the declining rate of successful pregnancy 
outcomes.  
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Women should be sensitively informed that risk of pregnancy loss increases after 35 
years of age. At age 40, successful pregnancy rate can be less than 50% (Lund et al., 
2012). 
In comparison, increasing male age has an association with incidence of miscarriage 
but it’s importance in RPL is uncertain (Sharma et al., 2015). 
 
Stress 
Couples should be informed that there is no evidence that stress is a factor leading 
to pregnancy loss (Nelson et al., 2003; Plana-Ripoll et al., 2016). There are several 
studies that have shown the presence of higher stress levels in women with 
recurrent pregnancy loss compared to control groups (Kolte et al., 2015; Li et al., 
2012). The impact of stress on risk of recurrent pregnancy loss is unclear as the 
increased levels of stress could be as a result rather than a cause of recurrent 
pregnancy loss. 
Occupational and environmental exposure 
There are only a few small studies that examined exposure to occupational and 
environmental exposure as factors in recurrent pregnancy loss. Therefore, there is 
insufficient information to recommend protection against a particular agent (Gold 
& Tomich, 1994; Pathak et al., 2010). However, general advice on avoiding possible 
hazardous substances during any pregnancy should be given. 
Chronic endometritis 
Chronic endometritis is a condition where plasma cells infiltrate the endometrium. 
Research has shown a wide prevalence range in women with recurrent pregnancy 
loss depending on method of detection used (Bouet et al., 2016; Cicinelli et al., 2014; 
Kitaya, 2011; McQueen et al., 2014; McQueen et al., 2015; Russell et al., 2013). 
However, screening women for endometritis is not currently recommended as there 
are no studies comparing the prevalence in a control group and whether treatment 
improves pregnancy outcomes. 
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Impaired endometrial decidualization 
Endometrial decidualization during a menstrual cycle and early pregnancy appears 
to be important as a quality control point in the implantation process for normal 
embryos and recognition of abnormal embryos leading to rapid shed of the 
endometrium (menstruation) (Lucas et al., 2016). An excessively receptive 
endometrium to implantation of abnormal embryos leads to increased rate of 
pregnancy loss. Further prospective studies are needed before use in clinical 
practice. 
 
2. Health behaviour modifications 
All couples assessed for RPL should be counselled about modifiable health 
behaviours that can influence pregnancy or health. Some of these behaviours are 
discussed below: 
Smoking cessation 
Couples should be advised that smoking could have a negative impact on pregnancy 
and should be avoided even without evidence that it reduces chance of successful 
pregnancy in recurrent pregnancy loss (Wilcox et al., 1990; Zhang et al., 2010). 
Smoking is known to have a strong association to poor obstetric outcomes and 
general health (Leung & Davies, 2015). 
Body Mass index (BMI) 
Studies have found obesity (BMI >30kg/m2 according to WHO) is associated with 
pregnancy loss and poorer fertility treatment outcomes (Metwally et al., 2008; 
Pandey et al., 2010). Higher prevalence of RPL was found in obese women compared 
to those with a normal BMI (20-30 kg/m2) (Boots & Stephenson, 2011; Lashen et al., 
2004). A further study found that obese women were more likely to miscarry euploid 
embryos (RR 1.63; 95% CI 1.08-2.47) (Boots et al., 2014). It has been demonstrated 
that maternal obesity significantly increased the risk of miscarriage in unexplained 
RPL (OR 1.27; 95% CI 0.89-1.83) (Lo et al., 2012). There is no evidence on the effect 
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of weight loss on RPL. However, studies have shown improvement of fertility with 
weight loss (Pandey et al., 2010).   
In those with low BMI <18.5 kg/m2, there is a significant association with sporadic 
miscarriage but not to recurrent pregnancy loss (Bellver et al., 2003; Lo et al., 2012; 
Maconochie et al., 2007). 
On the basis that maternal obesity and being underweight can lead to obstetric 
complications and impact general health, couples should be advised to aim for a 
healthy BMI. 
Avoiding alcohol 
Excessive alcohol consumption is a proven risk factor for fetal disorder (fetal alcohol 
syndrome). Although there is no evidence of alcohol consumption’s role in recurrent 
pregnancy loss, a large proportion of studies have shown an increased risk of 
miscarriage in a dose-dependent association (Andersen et al., 2012; Avalos et al., 
2014; Maconochie et al., 2007). Therefore, couples with RPL are advised to limit 
alcohol consumption. 
 
3. Investigations and management in RPL 
Here, I will discuss the history, investigations and management options that need to 
be considered when assessing a couple with RPL. 
Medical and family history 
In the first visit for referral of RPL, a thorough history of medical and family history 
should be obtained from both the female and male partner. This would include 
information on risk factors and lifestyle issues as discussed previously. History on 
medical conditions such as thrombophilia, polycystic ovarian syndrome (PCOS), 
diabetes, thyroid disease and family history of hereditary thrombophilia should be 
taken. The information from each couple can be used to select the appropriate 
investigations for RPL, as not all are relevant to every couple.  
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Genetic factor 
Chromosomal abnormalities and aneuploidy of the conceptus are recognised causes 
of sporadic and recurrent pregnancy loss (van den Berg et al., 2012). This can be 
investigated by karyotyping the pregnancy tissue following a miscarriage (Mathur et 
al., 2014). Currently, the best method of genetic analysis is array-based comparative 
genomic hybridisation (array-CGH) as it reduces maternal tissue contaminate 
(Kudesia et al., 2014; Mathur et al., 2014). There are limitations in the test in 
detection of balanced rearrangements, low-level mosaicism and minor copy number 
variants (Freeman et al., 2006; Sahoo et al., 2017). The newer technique of next 
generation sequencing (NGS) may change the choice of test in the near future 
(Shamseldin et al., 2013).  
Detection of chromosomal abnormalities does not translate into a prognostic test or 
offer of treatment. However, it can provide couples with an explanation for why the 
miscarriage occurred. It may also suggest an underlying condition if the couple 
miscarry a normal embryo.  
Parental karyotyping may be beneficial in a select group of couples with RPL. The 
test can detect presence of reciprocal translocation, inversion, Robertsonian 
translocation and other abnormalities. It can be recommended based on genetic 
history, which include previous child born with congenital abnormalities, detection 
of translocation in pregnancy tissue or family history of unbalanced chromosome 
abnormalities. The test has very limited value in other couples, as the rate of an 
abnormal karyotype is very low (Franssen et al., 2005; Franssen et al., 2006). 
This test can provide information on a contributing factor and prognosis for future 
pregnancies. In couples with abnormal results, the cumulative live birth rate is still 
good despite higher risk of RPL (Flynn et al., 2014). Prenatal diagnosis or pre-
implantation genetic testing can be offered to them as treatment after provision of 
information and genetic counselling. 
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Thrombophilia screen 
Thrombophilia is a condition that predisposes women to venous thromboembolism 
and can be acquired or hereditary. Acquired thrombophilia has a strong link to RPL 
but the association of the hereditary form of thrombophilia with RPL is still unclear. 
 
 Antiphospholipid Syndrome (APS) 
APS is the acquired form of thrombophilia. The diagnosis is made on persistent titres 
of antiphospholipid antibodies and vascular thrombosis and/or pregnancy 
complications (Miyakis et al., 2006). The tests that show a strong association with 
early or late miscarriage are lupus anticoagulant (LA) and anticardiolipin antibodies 
(ACA, IgG and IgM), while β2 glycoprotein I antibodies (aβ2GPI, IgG and IgM) show 
possible association but not statistically significant (Opatrny et al., 2006). An 
international consensus meeting recommended APS testing to women with a history 
of two or more pregnancy losses (Bender Atik et al., 2018; van den Boogaard et al., 
2013). 
It is recommended that women diagnosed with APS and a history of at least three 
miscarriages, be started on aspirin 75 to 100 mg daily pre-conceptually and to start 
prophylactic dose of heparin from date of positive pregnancy test (Bender Atik et 
al., 2018). 
 
 Hereditary Thrombophilia 
Hereditary thrombophilia includes Factor V Leiden mutation, Prothrombin gene 
mutation, Antithrombin, Protein C and Protein S deficiency. Due to paucity of 
evidence, screening and anticoagulant treatment for hereditary thrombophilia is not 
advocated outside of a research setting or in women with additional risk factors for 
thrombophilia. 
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Factor V Leiden mutation leads to its resistance to cleavage by activated protein C. 
this mutation appears to have a significant association to risk of a further pregnancy 
loss in the next pregnancy (Bradley et al., 2012). However, there is a paucity of 
evidence on treatment improving pregnancy outcomes.  
Prothrombin gene mutation raises plasma concentration of prothrombin. The 
evidence on the association between RPL and prothrombin gene mutation is not 
strong. The risk of a further pregnancy loss was not significant with minimal clinical 
utility (Bradley et al., 2012; Rey et al., 2003).  
In antithrombin, Protein C and Protein S deficiency, there is no significant association 
to women with RPL or difference in live birth rate compared to controls (Matsukawa 
et al., 2017; Rey et al., 2003). 
 
Immunological screen 
 Human leukocyte antigen (HLA) and cytokines 
It has been suggested that increased compatibility in HLA between partners 
decrease immune tolerance to the fetus. Evidence for compatibility of HLA between 
partners does not show a difference between women with RPL and controls 
(Beydoun & Saftlas, 2005). Measuring cytokine levels (e.g. TNF-α) and cytokine 
polymorphisms should not be tested in clinical practice as the relevance and 
evidence is unclear (Calleja-Agius et al., 2012; Choi & Kwak-Kim, 2008; Lee et al., 
2013; Medica et al., 2009; Mueller-Eckhardt et al., 1994). Therefore, HLA 
determination and cytokine testing in women with RPL is not recommended.  
 Antinuclear antibodies (ANA) 
ANA are antibodies against components of cell nuclei found in many autoimmune 
diseases. Most studies have found an association of positive ANA with RPL and 
poorer pregnancy outcomes (Cavalcante et al., 2015; Christiansen, 1996; Harger et 
al., 1983; Ogasawara et al., 1996; Stern et al., 1998). However, the pathophysiology 
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is unclear and response to immunotherapy is unknown. Therefore, ANA testing has 
limited clinical utility. 
 Natural Killer cells 
There are two forms of investigations, which are tests of cytotoxicity of peripheral 
blood NK cells and uterine NK cells in pre-conceptual endometrial biopsies from 
women with history of RPL. Currently, there is insufficient evidence to recommend 
NK cell testing for women with RPL.  
There is conflicting evidence for an association of high percentage or increased 
cytotoxicity of NK cells in peripheral blood and RPL (Chao et al., 1995; Emmer et al., 
2000; King et al., 2010; Kwak et al., 1995; Lee et al., 2013; Liang et al., 2012; Wang 
et al., 2008). In addition, studies did not find that high NK cell cytotoxicity had an 
impact on subsequent miscarriage rates (Emmer et al., 1999; Katano et al., 2013; 
Liang et al., 2012). 
Most studies have shown uterine NK cells are higher in women with RPL (Clifford et 
al., 1999; Quenby et al., 2005; Shimada et al., 2004; Tuckerman et al., 2007). 
However, the percentage of uNK cell density has not been able to predict 
subsequent pregnancy outcome (Liu et al., 2014; Tuckerman et al., 2007).  
There is also a significant difference between peripheral NK cells and uterine NK cells 
levels (Bender Atik et al., 2018). This means the peripheral NK cell test is unable to 
identify women with RPL for immunological treatments. Furthermore, the uNK cell 
tests are limited by inherent test errors involving interobserver variation, timing of 
the biopsy in the menstrual cycle and consensus on the normal range of the test. 
 
Metabolic and endocrine factors 
 Thyroid Dysfunction 
Thyroid dysfunction and increased thyroid peroxidase antibodies (TPO-Ab) have 
been linked to aberrant fertilisation and embryogenesis which may lead to 
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subfertility and pregnancy loss (Vissenberg et al., 2015). Hyperthyroidism is known 
to cause several pregnancy complications which include sporadic pregnancy loss and 
preterm delivery (Andersen et al., 2014; Bahn et al., 2011; Springer et al., 2017). 
However, there is no evidence on its effect on RPL (Bender Atik et al., 2018). 
Studies report higher prevalence of hypothyroidism and increased levels of TPO-Abs 
in women with RPL (Rao et al., 2008; Ticconi et al., 2011). In hypothyroidism and 
subclinical hypothyroidism, no difference was found in pregnancy outcomes 
compared to control groups (Bernardi et al., 2013; Rao et al., 2008; van den 
Boogaard et al., 2011; van Dijk et al., 2016). The association between thyroid auto 
immunity and RPL is clearer as the odds for a further pregnancy loss in women 
positive for TPO-Abs appeared to be significantly higher than that of controls 
(Thangaratinam et al., 2011; van den Boogaard et al., 2011). 
Hence, thyroid screening should be offered to women with RPL. Hypothyroidism 
should be treated with levothyroxine with monitoring of TSH and T4 levels.  
 PCOS 
There is conflicting evidence about the prevalence of PCOS and insulin resistance in 
women with RPL (Craig et al., 2002a; Maryam et al., 2012; Okon et al., 1998; Sagle 
et al., 1988). There is also no evidence to suggest increased risk of further pregnancy 
loss and there was no difference in predicting live birth rate compared with controls 
(Liddell et al., 1997; Rai et al., 2000).  
Therefore, assessment of PCOS, fasting insulin or glucose is not recommended. 
 
Anatomical factors 
Congenital uterine malformations show a clear association with RPL. These 
malformations encompass the septate uterus, bicornuate uterus, didelphic uterus 
and unicornuate uterus, and the prevalence of these findings are higher in women 
with RPL (Chan et al., 2011b; Saravelos et al., 2008). These women also have higher 
prevalence of first and second trimester miscarriage when compared to controls 
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(Chan et al., 2011a; Venetis et al., 2014). Despite this, how these malformations 
contribute to pregnancy loss and how treatment effects future pregnancy outcome 
is still unclear. 
Acquired uterine malformations include submucous fibroids, endometrial polyps 
and intrauterine adhesions. The prevalence of these findings is again high in women 
with RPL but its contributory factor to further pregnancy loss is uncertain (Hooker et 
al., 2014; Saravelos et al., 2011). Further studies are required to ascertain the clinical 
relevance of both congenital and acquired uterine malformations. However, due to 
the high prevalence, all women with RPL should have an assessment for uterine 
anatomy. 
The preferred non-invasive diagnostic test for congenital uterine malformations is a 
transvaginal 3D ultrasound scan (Caliskan et al., 2010; Ghi et al., 2009; Saravelos et 
al., 2008). The same diagnostic technique can be used for acquired uterine 
abnormalities but there is no strong evidence on which method is preferred. A 
hysteroscopic procedure would allow for the option of treatment in the same 
setting.  
Treatment of uterine abnormalities depends on type and severity. There is still 
insufficient evidence that surgical removal of submucous fibroids, endometrial 
polyps or intrauterine adhesions improves pregnancy outcomes in women with RPL. 
Hysteroscopic resection of uterine septum for RPL should be evaluated in a research 
setting as high-quality studies are needed (Kowalik et al., 2011; Rikken et al., 2017). 
Male factor 
There is conflicting evidence on the association of poor sperm parameters (sperm 
volume, count, reduced viability, abnormal morphology and reduced total 
progressive sperm motility) and RPL (Anifandis et al., 2014; Bhattacharya, 2008; 
Jensen et al., 2014; Pacey et al., 2014; Showell et al., 2014). A number of studies 
addressed male genetic defects and impact on RPL. The only significant association 
was higher miscarriage rates in men with high sperm DNA fragmentation compared 
to men with low sperm DNA damage (Robinson et al., 2012; Zhao et al., 2014). 
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Smoking, obesity and excessive exercise appear to cause oxidative stress that can 
lead to DNA fragmentation (Aitken et al., 2009; Du Plessis et al., 2010; Hsu et al., 
2009). Hence, clinicians should encourage the male partner to make healthy lifestyle 
modifications. More studies are needed to elucidate prognostic value of testing DNA 
fragmentation. 
Treatment of unexplained RPL 
Unexplained RPL is an area that is difficult to manage and evidence is mainly derived 
from poor quality or small studies. Some therapies have moderate or serious 
adverse effects with no significant effect on live birth rate and should not be offered 
or only considered in a research setting. This includes lymphocyte immunization 
therapy (Christiansen et al., 1994; Wong et al., 2014), intravenous immunoglobulin 
(IVIG) (Egerup et al., 2015; Hutton et al., 2007; Wang et al., 2016), prednisolone 
therapy (Gomaa et al., 2014; Laskin et al., 1997) and heparin or low dose aspirin (de 
Jong et al., 2014; Pasquier et al., 2015; Schleussner et al., 2015).  
The use of progestogen in unexplained RPL remains controversial. In a couple of 
recent large RCTs, there was no evidence to support use of vaginal progesterone in 
unexplained RPL (Coomarasamy et al., 2015; Kumar et al., 2014). However, a 
Cochrane systematic review of 11 trials which included 2359 women, found 
moderate evidence that progestogen probably reduces the number of miscarriages 
compared to placebo or controls in unexplained RPL (Haas et al., 2018). 
Further research is required to assess the treatment potential of glucocorticoids, 
granulocyte-colony stimulating factor (G-CSF) and endometrial scratch (Evers, 2016; 
Santjohanser et al., 2013; Scarpellini & Sbracia, 2009) as they have shown some 
beneficial effects. Current evidence does not recommend use of intravenous 
immunoglobulin or intralipids (Empson et al., 2005; Meng et al., 2016). 
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1.1.3 Recurrent implantation failure 
 
Definition of Recurrent Implantation Failure 
Recurrent implantation failure (RIF) has been used to describe failure of embryos to 
implant following repeated IVF cycles since 1983 (Potdar et al., 2013). However, 
there is no unanimous definition of RIF in the number of failed IVF cycles or number 
of embryos transferred that have not implanted (Polanski et al., 2014; Rinehart, 
2007; Simon & Laufer, 2012). The ESHRE PGD Consortium in 2005, suggested that 
RIF be considered after three or more high quality embryo transfers or implantation 
failure with transfer of more or equal to 10 embryos in multiple transfers with exact 
numbers to be determined by each centre (Thornhill et al., 2005). Majority of 
centres in UK use the definition of ≥ 3 failed IVF/ICSI cycles where good quality 
embryos were transferred (Tan et al., 2005).  
A systematic review assessing the definition of RIF was conducted by Polanski and 
group in 2014. It found significant heterogeneity in the definitions used. It is also 
unclear when implantation failure can be diagnosed. There is controversy about 
whether biochemical pregnancy losses should be classified as implantation failures 
(Coughlan et al., 2014). In vitro studies have shown that HCG levels increase in 
developing embryos around day 7 of fertilisation and HCG is an important hormone 
in the implantation process. However, a clear timepoint to confirm implantation is 
yet unknown. The authors of the systematic review suggest RIF be defined as 
absence of implantation, itself defined as a negative serum HCG 14 days after oocyte 
collection, after 2 consecutive cycles of IVF, ICSI or FET, where the cumulative 
number of transferred embryos was no less than 4 cleavage stage embryos and no 
less than 2 blastocyst stage with all embryos being of good quality and of 
appropriate development stage (Polanski et al., 2014). 
The main limitation of the review is the fact that it spans over two decades and the 
definition of RIF is required to shift and evolve with time, in light of new 
developments (Polanski et al., 2014). Most important developments are the practice 
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of transferring blastocyst stage embryos instead of cleavage stage and the move to 
single embryo transfer instead of multiple, in cycles with good quality embryos. 
All of the above, highlights the need for an internationally agreed consensus on the 
definition of RIF. This is paramount to address the limited scientific evidence and 
often empirical approach to investigations and treatment of RIF, by enabling 
research on a focused study population.  
The clinical challenge of RIF 
RIF is a formidable clinical challenge for clinicians and a devastating scenario for 
patients. Various investigations and treatment adjuncts have been studied to 
improve pregnancy outcomes in women with RIF. Not all approaches are evidence-
based and concerns have been raised that interventions have been introduced 
without sufficient supportive evidence.  
A good understanding on the factors required for successful implantation is 
paramount to guide investigations and management in RIF. Implantation is a 
complex process that involves two players: the mother and the embryo. This cross-
talk has been described in a previous section. A supportive maternal host 
environment and a good quality embryo requires synchronous interaction at the 
appropriate time (window of implantation) to achieve implantation and ultimately 
a successful pregnancy. 
In the assessment of couples with RIF, there is an overlap with the clinical approach 
used with those who suffer with RPL. History taking is crucial from both partners and 
the same modifiable health behaviours are relevant as discussed in a previous 
section. Couples with RIF can also be affected emotionally and psychologically. There 
is the added financial burden in proceeding with further IVF/ICSI treatment and need 
for open discussions on future success rates. Fertility counselling is a crucial resource 
in supporting these couples in making decisions about treatment, with a pragmatic 
and considered approach. 
In the following paragraphs, I have discussed the possible factors leading to RIF, their 
credence and respective treatment strategies.  Currently, there is little evidence to 
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guide practice in this difficult clinical challenge and reflects the difference in practice 
across the UK (Tan et al., 2005). In the midst of this, as clinicians, we meet desperate 
couples and it is incumbent on us to counsel based on available evidence and 
chances of success in future treatments. 
Treatment strategies in RIF aim to review previous fertility treatment and investigate 
possible causal associations as a consequence of embryo or endometrial factors. 
 
Embryo factors 
The quality of the embryo is influenced by oocyte quality, paternal sperm factors, 
the ability to fertilise and cleave. In addition, the embryo needs to signal to the 
maternal endometrium to facilitate implantation. Despite the definition of RIF to 
only include good-quality embryos, some morphologically normal embryos of good 
quality still cease to develop in utero and/or fail to implant. This can be due to 
suboptimal local condition or intrinsic factors within the embryos. 
 
1. Oocyte quality 
Poor oocyte quality can be established by poor response to ovarian stimulation and 
functional ovarian tests. The ovarian function tests include antral follicle count, basal 
FSH levels and anti-Mullerian hormone levels. There is age-related association with 
increased chromosomal nondisjunction leading to aneuploidy and increase 
mitochondrial DNA damage (Wang et al., 2009). Obesity also appears to affect the 
quality of oocyte and follicular development (Fedorcsák et al., 2000). The previous 
ovarian stimulation protocols used should be reviewed in order to ascertain the 
possible oocyte contribution to RIF. 
 
2. Sperm contribution 
Sperm is important in the development of a normal, good quality embryo. The male 
partner is generally advised to stop smoking and modify lifestyle behaviour. 
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However, no treatment strategies aimed at improving sperm quality have been 
shown to improve pregnancy outcome. Investigations and treatments should be 
conducted in a research setting. Current evidence does not support sperm DNA 
fragmentation as an important association in RIF or that sperm DNA integrity testing 
has value (Bronet et al., 2012; Coughlan et al., 2015). The recent RCT comparing 
physiological, hyaluronan-selected-ICSI (PICSI) and ICSI, recruited 2772 couples, and 
showed no significant difference in outcomes of live birth rates (Miller et al., 2019). 
There are significant differences in the way these tests are performed and 
interpreted.  
 
3. Genetic cause 
Structural chromosomal abnormalities in parents can lead to recurrent reproductive 
failure including implantation failure (Raziel et al., 2002). There is a higher 
prevalence of balanced translocation in couples with RIF with 2.5% in unexplained 
RIF (Raziel et al., 2002; Stern et al., 1999). Karyotype testing for specific couples 
should be considered (Coughlan et al., 2014). In the presence of structural anomaly, 
pre-implantation genetic diagnosis can be discussed. 
However, pre-implantation genetic screening (PGS) in unexplained RIF is 
controversial. The frequency of aneuploidy is similar in couples with or without RIF 
(Baart et al., 2006; Pehlivan et al., 2003). In a 2006 Cochrane systematic review, nine 
trials met the inclusion criteria and the authors found that live birth rate was 
significantly reduced in the group that had IVF/ICSI with PGS (Twisk et al., 2006). PGS 
technology has advanced in the last decade and further RCTs are urgently needed 
to evaluate the risk and benefit of PGS. It is also recognised that chromosomal 
mosaicism in blastomeres effect a large proportion of human embryos but do not 
necessarily lead to poor outcome (Harper et al., 1995; Munne et al., 1997; Voullaire 
et al., 2000). 
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Maternal host environment 
The only evidence-based investigations or treatment to ensure a supportive 
maternal host environment include identifying abnormal congenital or acquired 
anatomical factors and impaired endometrial function. There has been no 
association found between maternal thrombophilia and IVF failure (Martinelli et al., 
2003; Simur et al., 2009). Therefore, assessing thrombophilia status should not be 
performed. Immunologic investigations or treatment are also controversial as 
evidence is not strong for an association and is conflicting (Blois et al., 2011; 
Gellersen et al., 2007; Koot et al., 2012; Makrigiannakis et al., 2011). 
Next, I discuss the anatomical factors in RIF, the thin endometrium, treatment 
strategy of endometrial injury in preceding cycle to further IVF/ICSI treatment and 
endometrial receptivity. 
 
1. Anatomical factors 
Anatomical factors include the presence of uterine fibroids, uterine septum, uterine 
synechiae, endometrial polyps and hydrosalpinx. The evidence varies in how each of 
these factors and their management affect pregnancy success. Evidence is stronger 
for removal of hydrosalpinx, submucous fibroids and endometrial polyps (Demirol & 
Gurgan, 2004; Margalioth et al., 2006). With these findings, ART is delayed until 
these factors are managed surgically to improve success rates of treatment.  
Submucous fibroids distorting the uterine cavity reduce pregnancy and implantation 
rates (Bernard et al., 2000; Farhi et al., 1995; Narayan et al., 1994; Varasteh et al., 
1999). The suggested mechanism how distorting fibroids affect pregnancy outcome 
is by increased uterine contractility, abnormal vascularization and chronic 
inflammation (Buttram & Reiter, 1981). In a systematic review and meta-analysis, 
hysteroscopic resection of these fibroids was found to improve pregnancy rates 
(Pritts et al., 2009). However, there was no improvement in outcomes when 
myomectomy is performed for intramural fibroids that are not distorting the uterine 
cavity (Metwally et al., 2011; Pritts et al., 2009; Sunkara et al., 2010).  
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Endometrial polyps and intrauterine adhesions may interfere with implantation 
rates (Dawood et al., 2010; Pace et al., 2003; Richlin et al., 2002; Yasmin et al., 2007). 
Hysteroscopic removal of endometrial polyps is generally performed and a 
systematic review showed doubling of clinical pregnancy rate in intrauterine 
insemination cycles following this procedure (Bosteels et al., 2010). However, in a 
Cochrane systematic review no conclusion could be made on efficacy of endometrial 
polyp removal (Jayaprakasan et al., 2014). Furthermore, there is insufficient 
evidence to support hysteroscopic adhesiolysis for intrauterine adhesions due to 
small numbers in studies and the possibility of recurrence of adhesions (Dawood et 
al., 2010). 
The strongest evidence available on improving pregnancy outcomes for anatomical 
factors is found following treatment of hydrosalpinxes. It is suggested that 
hydrosalpinxes can have direct embryotoxic effects, mechanical flush out and 
negative effect on receptivity of the endometrium (Bildirici et al., 2001; Seli et al., 
2005). A prospective randomised controlled trial has shown that salpingectomy over 
no intervention improves live birth rate (LBR) (Strandell et al., 1999). 
In contrast, the most common congenital defect is a uterine septum. There is some 
evidence that a uterine septum is associated with repeated miscarriages but its role 
in infertility is unclear (Fedele et al., 2013; Pabuçcu & Gomel, 2004; Raga et al., 
1997). There is insufficient evidence to recommend hysteroscopic septum resection 
outside research projects as reviewed by National Institute for Health and Care 
Excellence (NICE) guidelines in 2015 titled ‘Hysteroscopic metroplasty of a uterine 
septum for primary infertility’. This conclusion is again confirmed by a Cochrane 
systematic review in 2017. The results of the nine trials that met the inclusion criteria 
was conflicting and there are two ongoing trials (Rikken et al., 2017). A limitation of 
such RCTs is the low number of women with uterine septum and difficulty in 
recruiting. 
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2. Impaired endometrial function 
Impaired endometrial function is an area that has been researched and multiple 
therapies have been suggested. However, evidence for the efficacy of these 
interventions is limited. The aspects of endometrial function that I will explore are 
‘the thin endometrium’, endometrial scratch and endometrial receptivity.  
The thin endometrium 
One suggested optimum endometrial thickness for ART and implantation is ≥ 9mm 
(Noyes et al., 1995). More recent studies suggest that an optimum endometrium is 
one with thickness of 7 or 8mm on day of HCG trigger (Liu et al., 2018; Yuan et al., 
2016). This is a marker of endometrial function and ability to support an implanted 
embryo and placentation. However, a recent meta-analysis has shown that 
endometrial thickness is a poor predictor of pregnancy outcome casting doubt on 
the validity of this test (Weiss et al., 2017).  In particular, an endometrium thickness 
< 6mm, presents a difficult clinical situation to manage, ‘the thin endometrium’ 
(Abdallah et al., 2012; Shufaro et al., 2008). In a large Canadian cohort study of 
24363 fresh and 20114 frozen cycles over 3 years, clinical pregnancy and live birth 
rate declined with each mm decrease in endometrial thickness <8mm in fresh cycle 
and <7mm in frozen cycle. However, they conclude that pregnancy outcomes were 
reasonable for endometrial thickness of 4 to 6mm (Liu et al., 2018). These outcomes 
may reassure clinicians and patients who have persistently thin endometrium. This 
is particularly important as no therapy has been found to improve pregnancy 
outcomes. 
The therapies that have been suggested include high dose oestrogen to prime the 
endometrium, use of aspirin and increasing blood flow to the endometrium (Simon 
& Laufer, 2012). Sildenafil is an agent that causes vasodilatation and is used to 
increase blood flow to the endometrium to encourage development of the 
endometrium in preparation for implantation. However, there have been no high 
quality randomised controlled trials that demonstrate that this approach is 
efficacious in improving live birth rates and this view is supported by a recent 
Cochrane systematic review (Gutarra-Vilchez et al., 2018). Recent research has 
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explored granulocyte colony-stimulating factor as a treatment option. The evidence 
is conflicting but has not shown increase in live birth rates (Aleyasin et al., 2016; 
Kunicki et al., 2017; Zhang et al., 2018). 
 
Endometrial injury in ART 
Mechanical stimulation of the endometrium using an endometrial sampling 
catheter, in the cycle preceding treatment may be beneficial in certain subgroups of 
women (Narvekar et al., 2010; Raziel et al., 2007). This is supported by a Cochrane 
review which found increased live birth rate following endometrial injury in women 
with RIF and > 2 previous embryo transfers (Nastri et al., 2015). Other systematic 
reviews and meta-analysis found similar results (El-Toukhy et al., 2012; Potdar et al., 
2012). It is postulated that this endometrial injury provokes an immune response 
that encourages the endometrium to prepare for implantation (Gnainsky et al., 
2010). More information is needed to understand the underlying process of 
mechanical stimulation.  
 
Endometrial Receptivity Array test 
Endometrial tests such as the Endometrial Receptivity Array test is a novel technique 
to allow estimation of when the window of implantation will take place. This test 
examines a small amount of tissue from the endometrial lining and analyses  
presence of over 200 genes associated with implantation (Garrido-Gómez et al., 
2013). Studies have found, this window can vary and better recognition of the 
‘window of implantation’ may suggest options to manipulate this crucial period and 
facilitate the cross-talk between the embryo and its platform (Sebastian-Leon et al., 
2018). Moving the timing of planned embryo transfer to the appropriate time is 
hoped to improve the chance of successful implantation (Ruiz-Alonso et al., 2013; 
Sebastian-Leon et al., 2018). A randomised controlled trial is ongoing to assess the 
efficacy of this approach. Currently, there is still insufficient evidence to determine 
improvement of pregnancy outcomes. 
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Recently, the concept that RIF is more than asynchrony of endometrial maturation 
and therefore receptivity, has emerged. This supports the idea that endometrial 
receptivity is determined by a multitude of factors (Koot et al., 2012). Advancements 
in technology have open avenues for future research allowing exploration of gene 
expression during decidualisation. Research has demonstrated a specific 
transcriptomic signature in RIF when compared to controls (Koot et al., 2016; 
Macklon, 2017). Further work, has also shown a differential constitutive disruption 
of endometrial gene expression in women with RIF (Huang et al., 2017). Gene 
expression analyses appear able to classify women by severity of RIF phenotype and 
has the potential to elucidate underlying mechanisms of RIF that are yet unknown. 
 
Management of RIF 
Approach to management of couples with RIF should begin with a multi-disciplinary 
discussion consisting of a senior fertility specialist, senior embryologist and if 
appropriate reproductive surgeon and fertility counsellor. A thorough review of 
underlying cause of infertility, previous treatment results, treatment protocol, 
ovarian stimulation response, oocyte quality, fertilisation rates and quality of 
embryos should be conducted. This will guide modification and change treatment 
protocols as required. Any behavioural modifications that need to be undertaken 
should be discussed. Following this, careful consideration should be given to further 
investigations or therapies based on current evidence as discussed above. Main 
treatment strategy is to improve quality of embryo and receptivity of the 
endometrium. 
At present this process is problematic due to the dearth of evidence-based 
investigations or precision treatments available. Furthermore, there are a large 
number of expensive but not proven treatments.  
For the rest of my thesis, I will concentrate on the endometrial contribution to 
reproductive failure.   
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1.2 Endometrial factor in RPL and RIF 
 
In the Brosens research laboratory in Warwick Medical School, the focus has been 
on investigating the endometrium as a factor in recurrent reproductive failure. The 
Warwick paradigm is that the endometrium plays a crucial role in natural embryo 
selection (Brosens et al., 2014; Salker et al., 2010; Teklenburg et al., 2010) and 
sustaining pregnancies.  
 
1.2.1 Human Endometrium 
 
The endometrium is the inner epithelial layer of the uterus. It is a highly dynamic, 
cycling tissue that plays an important role in embryo selection.  
It consists of three layers: the stratum compactum, stratum spongiosum and 
stratum basalis. During the proliferative phase of the menstrual cycle, the stratum 
compactum and stratum spongiosum develop into the stratum functionalis.  
The functionalis region is made of the epithelium, endometrial human stromal cells, 
endometrial glands, immune cells and spiral arteries. The functionalis layer is under 
the influence of hormonal changes. It thickens with proliferation and changes to a 
mainly secretory tissue which sloughs off during menstruation. The basalis layer 
remains following menstruation and contains vessels (short, straight basilar arteries) 
that spiral arteries originate from (Ganong, 2003). 
Before puberty and following menopause, this tissue is morphologically constant. At 
menarche, the endometrium prepares for embryo implantation in a cyclical pattern 
dependent on hormonal control of the hypothalamic-pituitary-ovarian axis. The 
three phases are the follicular phase (proliferative), luteal phase (secretory) and 
menstruation if no embryo implants. This process is described next. 
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1.2.1.1 Hypothalamus-pituitary-ovarian axis 
 
Hypothalamic-pituitary-ovarian axis (HPO-axis) 
 
Figure 1. 4: Hypothalamic-pituitary-ovarian axis (HPO-axis) in human menstrual cycle. (By 
courtesy of Encyclopaedia Britannica, Inc., copyright 2013; used with permission.) 
 
Oestrogen and progesterone are key hormones for steroid action within the 
endometrial cycle. These hormones are released by the ovaries. The ovaries are 
regulated by pituitary hormones that are under direct control of the hypothalamus. 
In the hypothalamus, neurons secrete pulsatile gonadotrophin-releasing hormone 
(GnRH) which travel along the portal vessels and bind to basophil gonadotroph cells 
in the anterior pituitary gland. This causes the synthesis and release of 
gonadotrophin hormones; follicular-stimulating hormone (FSH) and luteinising 
hormone (LH). FSH and LH regulate ovarian hormone production and the growth and 
release of oocytes.  
Within each menstrual cycle, around 15 to 20 antral follicles are recruited by FSH 
and LH (Scheffer et al., 2003). This occurs following menstruation at around day 4. 
At the same time, the smaller follicles release inhibin B which provides negative 
feedback and inhibits basal FSH secretion. Follicular development and synthesis of 
oestradiol are dependent on FSH, LH, granulosa cells and theca cells. As the follicles 
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grow, oestradiol levels increase and exerts a negative feedback on the HPO-axis. This 
ensures one follicle becomes dominant per cycle and ovulates. When this follicle is 
mature, high concentrations of oestradiol cause a change to a positive feedback at 
the pituitary and hypothalamus. This causes the LH surge and ovulation around 36 
hours later. The corpus luteum is formed by the remaining granulosa and theca cells 
following ovulation. The LH surge also causes the luteinisation of these granulosa 
cells enabling synthesis of progesterone. The corpus luteum produces large amount 
of progesterone to stabilize the endometrium in preparation for pregnancy. If 
conception does not occur, the corpus luteum regresses and progesterone levels 
fall. This withdrawal causes menstruation and FSH to increase for the next cycle. 
 
1.2.1.2 Menstrual cycle 
The diagram below illustrates the interaction between hypothalamic-pituitary-
ovarian axis and the endometrium. 
 
Figure 1. 5: The menstrual cycle. The HPO-axis exerts hormonal control on the ovaries 
which secrete oestrogen and progesterone. Oestrogen and progesterone drives 
proliferation and decidualisation of the endometrium. (By courtesy of Encyclopaedia 
Britannica, Inc., copyright 2013; used with permission.) 
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Endometrial changes in the menstrual cycle (28 days cycle) 
1. Proliferative Phase (follicular) – Day 4 to 14 
Following menstruation and repair, oestradiol is secreted by the developing ovarian 
follicles. This leads to endometrial proliferation and stimulates expression of both 
the oestrogen receptor and progesterone receptor across all cell types (Bouchard et 
al., 1991). The functionalis layer of the endometrium is the site of intense mitosis 
creating a thickened endometrium consisting of glands supported by stroma 
(Brenner et al., 2003a; McClellan et al., 1986). Studies have demonstrated that the 
basalis layer may not be the source of stem cells for endometrial regeneration but 
changes in the microenvironment may re-programme the functionalis cells 
remaining to regenerate a new functionalis layer (Horne & Blithe, 2007). 
The endometrial epithelium is formed again and some are ciliated. The endometrial 
glands grow and lengthen with the increased thickness of the endometrium but are 
not convoluted and do not secrete. The spiral arteries begin to wind into the stroma. 
The end of the proliferative phase occurs when oestradiol peak exerts a positive 
feedback at the pituitary and initiates the LH surge causing ovulation around 36 
hours later. 
 
2. Luteal Phase (secretory) 
The corpus luteum is the remaining granulosa and theca cells following ovulation. It 
secretes progesterone which drives the transformation of the proliferative 
endometrium into the secretory structure required for implantation and pregnancy 
(Horne & Blithe, 2007). The endometrium becomes slightly oedematous and very 
vascular. The glands become coiled and torturous. They acquire glycogen and 
release glycoprotein secretions that support implantation. The spiral arteries 
entwine with the glands and become mature structures. The expression of 
oestrogen and progesterone receptors disappears about 7 to 10 days following 
ovulation which corresponds to the usual time of implantation (Wilcox et al., 1999). 
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The maximal receptive period for an embryo is the implantation window, which 
usually lies between day 20 to 23. 
The length of the luteal phase is remarkably constant at a duration of 14 days. 
3. Menstruation (Day 1 – 4) 
In the absence of conception, progesterone levels fall with the regression of the 
corpus luteum resulting in the loss of lysosomal integrity (Salamonsen et al., 1999). 
The functionalis layer undergoes enzymatic degradation, the spiral arteries constrict 
causing tissue necrosis and the layer is sloughed off in menstrual blood, which does 
not coagulate due to local fibrinolytic factors (Ganong, 2003).  
 
 
1.2.2 Assessing endometrial function 
1.2.2.1 Decidualisation 
 
Decidualisation is the transformation of endometrial stromal cells into specialized 
secretory decidual cells that provide a nutritive and immune privileged matrix 
essential for embryo implantation and placental development (Gellersen & Brosens, 
2014). Rising progesterone levels, paracrine signals and cellular cyclic adenosine 
monophosphate (cAMP) production that occur in the mid-luteal phase of a 
menstrual cycle initiates decidualisation. Decidualisation begins in the vicinity of the 
spiral arterioles and then spreads to encompass the whole superficial endometrial 
layer as the cycle progresses. In conjunction with stromal cell decidualisation, the 
endometrium undergoes extensive remodelling that is affected by the influx of 
immune cells, predominantly uterine Natural Killer cells and macrophages. 
A significant body of evidence has shown that impaired decidualisation is associated 
to recurrent pregnancy loss and recurrent implantation failure (Brighton et al., 2017; 
Brosens et al., 2014; Gellersen et al., 2007; Lucas et al., 2016; Weimar et al., 2013). 
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Decreased endometrial mesenchymal stem cells (eMSCs) and accelerated stromal 
senescence has been implicated in the process of impaired decidualisation (Lucas et 
al., 2016). 
An important role of decidualisation is the ability to select normal from abnormal 
embryos. Decidualised human endometrial stromal cells (HESCs) from women with 
recurrent pregnancy loss discriminate less effectively between high and low-quality 
embryos and migrate more readily towards trophoblast spheroids (Salker et al., 
2010; Weimar et al., 2012). Due to this, some women with RPL are ‘superfertile’ as 
they have increased fecundity due to the loss of endometrial ability for embryo 
selection and allows implantation of low-quality embryos that are lost during 
menstruation in normal women but end in miscarriage in ‘superfertile’ women 
(Salker et al., 2010). In comparison, the endometrium in women with RIF has the 
opposite problem of being highly selective by inhibiting recognition and impairing 
the implantation of good quality embryos.  
In the following paragraphs, I explore how decidualisation is important for 
reproductive fitness in humans.  
Reproductive fitness  
Historically, knowledge of early reproductive events in humans have been derived 
from animal models. This is due to the ethical and legal restrictions inherent in this 
area of study. The mouse model has been the most commonly used due to its 
predictability, relatively short gestation and ability to deliberately breed mice with 
absence of a desired gene (Melford et al., 2014). However, as in most mammalian 
species, the murine embryo signals trigger decidualisation in an oestrous cycle. In 
contrast, the initiation of decidualisation in humans is uncoupled from embryonic 
signals (Teklenburg et al., 2010). In humans, ‘spontaneous’ decidualisation occurs in 
each menstrual cycle, irrespective of the presence of an embryo (Brosens et al., 
2002; Gellersen et al., 2007). This suggests significant difference in early pregnancy 
developments.  
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Both humans and mice develop haemochorial placentae which is the most invasive 
form of placentation. The difference is human embryos are more invasive and 
implant interstitially, deeply invading stroma cells, while the epithelium is restored 
over the conceptus (Melford et al., 2014). Therefore, human embryos are deeply 
invasive and require a large investment from the mother. This investment is mainly 
for a single human fetus, whereas mice have on average 6 in a litter and can have up 
to 10 litters a year. Gross embryonic chromosomal abnormalities are also rare in 
most mice strain (Teklenburg et al., 2010). Conversely, there is significant mosaicism 
in top-quality human embryos and intrinsic genomic instability. The presence of this 
genomic instability confers genetic diversity and adaptability; important for 
complex, high-functioning individuals.  
Another difference from the mouse model, is the ability of mice to delay 
implantation. The murine uterus remains quiescent causing embryos in a blastocyst 
state to remain dormant (embryonic diapause) (Lopes et al., 2004). A surge in 
ovarian oestradiol then triggers synchronized implantation of chromosomally stable 
murine embryos (Hamatani et al., 2004). Reproductive success in mice is based on 
quantity, rapid breeding cycles, multiple implantation events and litter sizes (Lucas 
et al., 2013). 
In all species, reproduction has a large energy cost and it is beneficial to have ideal 
conditions to ensure investment in competent embryos and offspring survival. The 
Warwick group proposes a variable endometrial strategy for human reproductive 
success which safeguards the mother against prolonged investment in invasive but 
developmentally abnormal embryos. In humans, the endometrium plays an active 
role in implantation and as an embryo sensor. The process of cyclic decidualisation 
and menstruation is believed to be an adaptive response to the high incidence of 
chromosomal instability in human embryos (Teklenburg et al., 2010). Decidualising 
stromal cells appear to have the ability to respond to individual embryos and either 
promote implantation and further development or facilitate early rejection 
(Macklon & Brosens, 2014). Therefore, failure or inadequacies of this process may 
disable natural embryo selection and lead to recurrent reproductive failure. 
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The ‘permissive’ and ‘selective’ endometrium 
Cyclical decidualisation enables the endometrium to adapt and rebalance its 
permissive and selectivity traits. The endometrium is termed permissive during its 
receptive phase or window of implantation and selective out of this phase (Gellersen 
& Brosens, 2014). In an ordered decidual response, the endometrial stromal cells 
are able to discriminate low- and high-quality embryos during the window of 
implantation (Macklon & Brosens, 2014). This system is capable of disposing of 
incompetent embryos prior to implantation and safeguarding the mother from 
investing in abnormal embryos. There are also additional mechanisms following 
implantation to ensure timely rejection of failing pregnancies. An embryo that 
secretes insufficient HCG is deemed to lack fitness and is unable to rescue the corpus 
luteum to support pregnancy leading to early miscarriage in the first few weeks. 
Beyond this near the end of the first trimester, the transition from histiotrophic 
nutrition to active maternal perfusion of the placenta serves as a robust stress test 
of the feto-maternal interface (Hempstock et al., 2003; Jauniaux et al., 2000). This 
ensures that if a pregnancy is poised to fail, it is most likely to fail before 12 weeks 
gestation. The balance of endometrial and embryonic phenotypes is postulated to 
ensure the likelihood of a successful pregnancy outweighs that of a clinical 
miscarriage (Gellersen & Brosens, 2014).   
 
Research has shown a prolonged and disordered proinflammatory decidual 
response in women with RPL (Salker et al., 2012). This proinflammatory decidual 
phenotype prolongs the window of receptivity and loses its ability to discriminate 
between low- and high-quality embryos in cell migration assays (Salker et al., 2010; 
Salker et al., 2011; Weimar et al., 2012). This highly receptive endometrium allows 
unhindered implantation leading to high number of subsequent pregnancy failures 
due to implantation of incompetent embryos. This paradigm can also explain the 
concept of ‘superfertile women’ who conceive rapidly but also have increased 
pregnancy losses due to aberrant embryo selection by the endometrium (Macklon 
et al., 2002; Salker et al., 2010; Wang et al., 2003). Conversely, it is postulated that 
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excessive or lack of decidualisation could increase the barrier function of the 
endometrium leading to implantation failure and conception delay (Gellersen & 
Brosens, 2014).  This may explain some of the underlying mechanisms in women 
with RIF. 
 
Figure 1. 6: Variable strategy of human endometrium in reproductive fitness. Gellersen, B. & 
Brosens, J. J. (2014) Cyclic decidualization of the human endometrium in reproductive health and failure. Endocr 
Rev, 35 (6): 851-905, by permission of Endocrine Society and Oxford University Press. 
The above figure shows the interaction between the maternal endometrium and the 
embryo. A highly receptive endometrium encourages pregnancy but losses its ability to 
discriminate between high and low- quality embryos leading to higher incidence of 
miscarriages. A highly selective endometrium discourages implantation and may cause 
implantation failure of good quality embryo. However, miscarriages are less likely to 
happen as no implantation occurs.  
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Differences in RPL and RIF 
Research has often combined RPL and RIF under the term recurrent reproductive 
failure. However, emerging evidence suggests that these are separate clinical 
entities that may sit on opposing ends of a spectrum of endometrial phenotypes. In 
reality, women’s endometrial phenotype likely changes on the scale of permissive 
and selective traits through adaptations in menstrual cycles. Menstruation 
showcases the remarkable ability of the endometrium to regenerate and recruits an 
abundance of adult stem cells (Du et al., 2012; Du & Taylor, 2010; Gargett et al., 
2012; Gargett & Ye, 2012).  
In RPL, the endometrium appears to be highly permissive and has lost its natural 
embryo selection ability. However, the chances of successful pregnancy outcomes 
following 3 miscarriages are good with or without intervention. This may be 
attributed to inter-cycle variation of the endometrium and exposure to a competent 
embryo following a high incidence of embryo chromosomal abnormalities. 
However, it is postulated that women with RIF and no history of RPL, have a highly 
selective endometrium. This endometrial phenotype does not only dispose of 
abnormal embryos but also competent ones prior to implantation. Therefore, no 
implantation takes place despite good quality embryos and women do not 
experience miscarriages. The underlying mechanism is still unclear but this paradigm 
supports the idea that RPL and RIF are a result of different aberrant processes 
(Gellersen & Brosens, 2014).  
If this disparity is true, then the future enrichment of study populations in recurrent 
reproductive failure must recognise the difference in these two groups. Further 
studies examining these mechanisms and endometrial plasticity are important to 
understanding the underlying pathophysiology before precision interventions can 
be developed that ensure reproductive fitness.  
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1.2.2.2 Endometrial function investigations 
 
It is clear that the human endometrium is a dynamic tissue that undergoes cyclical 
changes each month and requires balanced haemostasis to perform its role 
effectively. Research effort has focused on assessing endometrial function in the 
mid-luteal phase, when investigating underlying pathology and possible therapies 
for RPL or RIF. Assessment at this time provides information on the preparation of 
the endometrium for implantation. The aim of research is to identify abnormalities 
that lead to a highly receptive or restrictive endometrium leading to RPL or RIF, 
which would direct focused therapy. The following explores methods of 
investigation using mid-luteal endometrial biopsies. 
1. Endometrial histological dating 
As the basalis layer remains constant and is not under the influence of hormones, 
endometrial dating is performed on the functionalis layer. Traditionally, Noyes 
criteria has been used (NOYES, 1956; NOYES, 1963). It was developed on the 
morphological characteristics associated with the proliferative and luteal phase of a 
menstrual cycle.  
The limitations of this method include the poor inter-observer reproducibility 
(Coutifaris et al., 2004; Lessey et al., 2000; Myers et al., 2004). Histological 
classifications also do not address functional changes as seen with proliferative 
markers or steroid receptor expression. Detection and counting of proliferative cells 
are a better method to use in the proliferative phase. This has been measured using 
differing antibodies in immunohistochemistry and an example is Ki67 (Gerdes et al., 
1983) and phosphorylated histone H3 (Brenner et al., 2003b). In addition, the 
technique of endometrial biopsies through Pipelle sampling disrupts the spatial 
arrangement of tissue and does not represent the overall complexity for accurate 
histological dating (Horne & Blithe, 2007).   
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2. Genomic expression 
Research has studied genomic analysis as a means to classify endometrial biopsies 
into stages based on gene expression in each phase of the menstrual cycle. This 
would help overcome the inaccuracy found in histological endometrial dating. The 
Endometrial Receptivity Array test (ERA) used to investigate recurrent implantation 
failure and time the ‘window of implantation’ is an example. These methods are still 
being researched and requires specific expertise (Ruiz-Alonso et al., 2013; Sebastian-
Leon et al., 2018). Whilst the ERA test offers promise for improving endometrial 
function prior to embryo transfer, the test along with the suggested management of 
delaying transfer or increasing progesterone administration has not been proven 
with a published randomised-controlled trial. 
Genomic expression patterns in the endometrium can be separated based on 
steroid receptor patterns and the phase of the menstrual cycle with different effects 
in the stromal cells or the epithelial cells (Lessey, 2003; Talbi et al., 2006). Genes are 
expressed dependent on the roles required in each phase of the menstrual cycle 
(Houshdaran et al., 2014; Simon et al., 2009; Zelenko et al., 2012; Zhang & Ho, 2011).  
 
3. Uterine immune system 
Pregnancy is a unique and challenging condition for the maternal immune system. 
The maternal immune system must exhibit tolerance to the semi-allogenic embryo, 
while retaining appropriate immune responses to protect against local immune 
insults. This immunological paradox invokes multiple complex, overlapping and 
redundant mechanisms (Hyde & Schust, 2016). The mechanisms underpinning 
immune tolerance are crucially time and site specific. Understanding this process is 
complicated by limitations of human studies for logistic and ethical reasons. Hence, 
some insights have been garnered from animal studies only.  
The immune system has two parts; the peripheral and mucosal system. The 
peripheral system provides defence against blood-borne pathogens through 
functions of spleen, lymph nodes and peripheral blood. The mucosal or innate 
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immune system protects against pathogens that gain entry to the body through 
mucosal surfaces; at the respiratory, gastrointestinal and genitourinary tract. The 
innate immune system compromises of T cells, B cells (including IgA-secreting 
plasma cells), NK cells, macrophages and dendritic cells (Hyde & Schust, 2016; 
Kutteh, 2014).   
It is the innate immune system at the maternal-fetal interface, that confers immune 
tolerance needed for the establishment and maintenance of pregnancy in the pre- 
and peri-implantation period (Veenstra van Nieuwenhoven et al., 2003). This local 
system is unique as it has hormonal regulation in a tissue which requires constant 
transformation and adaptation. There are a series of mechanisms that exert this 
immune tolerance; which include absence of classical major histocompatibility 
complex (MHC) molecules on sperm, embryonic and trophoblast cells, alteration 
toward anti-inflammatory Th2 driven system and a unique population of immune 
cells (Hyde & Schust, 2016).   
 
Immune cell population 
 Decidual granular lymphocyte (uNK cells) 
The uterine Natural Killer (uNK) cells is the most abundant lymphocyte in the 
endometrial immune system during late luteal phase and early pregnancy (Johnson 
et al., 1999; Loke & King, 2000a; Loke & King, 2000b; Vince & Johnson, 2000). It is 
the major immune cell population at the early feto-maternal interface and the key 
regulators in supporting trophoblast invasion and of the maternal uterine 
vasculature remodelling (Hanna et al., 2006; Kopcow et al., 2005). This is one of the 
reasons that it has been extensively studied.  
Uterine NK cells express CD56+ CD16- a less toxic cell population compared to 
peripheral NK cells which mainly express CD56+Cd16+, a cytotoxic subset (Lee et al., 
2011). Uterine NK cells begin to increase in the mid-secretory phase and continues 
with a rapid rise in late luteal phase reaching 70% of uterine leucocytes (Flynn et al., 
2000). The levels reach a peak at the end of the first trimester (King et al., 1991). 
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These findings suggest uNK cells play a crucial role in the establishment and 
maintenance of a pregnancy. Active uNK cells secrete IL-15 and increase production 
of cytokines, growth and angiogenic factors (Hanna et al., 2006). In this manner, uNK 
cells contribute to embryo implantation and decidualisation of the endometrium 
(Manaster et al., 2008). More recent research has found that uNK cells also play a 
role in clearing endometrial senescent cells creating space within the functionalis 
layer of the endometrium which facilitates invasion of the implanting embryo 
(Brighton et al., 2017). 
 NKT cell 
NKT cells exhibit both NK and T cell characteristics (Boyson et al., 2002; Godfrey et 
al., 2000). NKT cell expansion is mediated by fetally expressed MHC Class I molecule 
from paternal genome in mice (Dang & Heyborne, 2001).  NKT cells are also present 
in human decidua and may represent a mechanism of fetal modulation on maternal 
immune response to induce tolerance and be involved in formation of Th2- 
dominant environment (Hyde & Schust, 2016).  
 T cell regulation 
T cells are present in low numbers in the late secretory phases (Johnson et al., 1999; 
Loke & King, 2000c; Vince & Johnson, 2000). The balance between effector and 
regulatory T cells are important for feto-maternal immune tolerance.  
MHC Class I molecules present endogenous antigens to T cell receptors (TCR) on 
CD8+ T cells. Although gametes and most placental cells are MHC Class I and II 
negative, the extra villous trophoblast cell does express non-classic MHC Class I 
molecules HLA-G, HLA-E and HLA-C (Hyde & Schust, 2016). This pattern of MHC 
expression may limit allorecognition reactions and promote uNK cell-mediated 
cytokine modulation and maternal vascular remodelling (Hyde & Schust, 2016).  
TCR on CD4+ T cells recognise antigen presented by MHC Class II molecules on 
antigen presenting cells and is a defence mechanism against exogenous pathogens 
(Hyde & Schust, 2016). These CD4+ cells are T helper and regulatory T cells.  
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Successful implantation requires tight control of inflammatory-type reactions. In 
particular, the Th 1 pro-inflammatory response which is seen in transplanted graft 
rejection (Zenclussen, 2013). Naive T helper cells (Th0) mature and differentiate 
depending on their cytokine microenvironment. T cells producing type 1 cytokines 
(Th1) causes a pro-inflammatory reaction in the initial process of embryo 
implantation and invasion of the endometrium (Mor et al., 2011). This is followed 
by a shift to an anti-inflammatory phase with T cells releasing type 2 cytokines (Th2) 
to establish the embryo, support rapid fetal growth and development by 
maintaining uterine quiescence (Szekeres-Bartho & Polgar, 2010). Other T helper 
cells include regulatory T cells (T regs) which are potent suppressors of inflammatory 
type 1 immune responses by suppressing inflammatory cytokine INF-γ secretion 
(Mao et al., 2010). T regs also suppress secretion of IL-4 against paternal antigens 
(Mjösberg et al., 2007). 
There are also many co-stimulatory signals which control response to antigens and 
assist immune tolerance by suppressing T cell activation, adaptations to promote 
antigen tolerance and T cell apoptosis (Freeman et al., 2000; Nagamatsu et al., 2011; 
Petroff & Perchellet, 2010). 
 Dendritic cells and decidual macrophages 
Dendritic cells and decidual macrophages are the major antigen presenting cells in 
the endometrium (Plaks et al., 2008). The colony-stimulating factor (CSF-1) secreted 
by endometrial epithelium, is the main regulator of mononuclear phagocytic lineage 
and controls the function of these two cell types (Pollard, 2008). Both affect immune 
tolerance and regulate angiogenesis (Nagamatsu & Schust, 2010). 
 B lymphocytes 
There are low numbers of B lymphocytes in the decidua, which aids in immune 
tolerance while retain pathogen surveillance ability (Aït-Azzouzene et al., 1998; 
Kutteh, 2014; Muzzio et al., 2016). These cells produce antibodies as a central 
component to the humoral immunity (Hyde & Schust, 2016).  
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Reproductive Hormonal Control 
Hormonal control of immune modulation and maintenance of semi-allogeneic fetus 
is provided by oestrogen, progesterone and human chorionic gonadotrophin (hCG) 
(Siiteri et al., 1977; Wira et al., 2014). High levels of oestrogen and progesterone 
appears to promote Th2 immune responses and enhance recruitment and 
proliferation of T regs (Correale et al., 1998; Cutolo & Wilder, 2000; Mao et al., 2010; 
Salem et al., 2000). HCG also sustains an anti-inflammatory effect and is a 
chemoattractant to T reg cells at the maternal-fetal interface (Schumacher et al., 
2009). 
In summary, the local immune system of the endometrium and of the maternal-fetal 
interface is a highly complex, multi-faceted process that is still not fully understood. 
Disruptions and aberrations in this process can lead to several complications such as 
RPL, RIF, preterm birth, pre-eclampsia and restricted fetal growth.  
 
1.3 Uterine Natural Killer (uNK) cell test 
 
One area of research, centres on the link between uNK cells and reproductive failure. 
As previously discussed, these lymphocytes are part of the innate immune system 
and are the most abundant lymphocyte found in the endometrium. uNK cells show 
the ability to interact with fetal trophoblasts and have a role in decidualisation, 
angiogenesis and clearance of acute cell senescence.  
Studies in luteal phase endometrium have shown that women with recurrent 
reproductive failure have higher density of uNK cells than controls (Clifford et al., 
1999; Quenby et al., 1999; Tuckerman et al., 2007). The uNK cell density test is 
performed in mid-luteal endometrial biopsies. This test has been adopted by many 
centres across the world to assess women with RPL or RIF. UNK cell density 
correlated well with in vitro models of decidualisation suggesting that the uNK cell 
density is functionally important (Kuroda et al., 2013). However, very little 
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prospective data exists to assess how good the test is at predicting pregnancy 
outcome (Tang et al., 2011). 
The normal range for uNK cell density was set by using a range determined from a 
group of women attending hospital in the mid-luteal phase for a laparoscopic 
sterilisation having completed their family with two or more live births (Quenby et 
al., 1999; Quenby et al., 2005). However, this normal range was based on a low 
number of samples. Recent research in China has supported these findings of a 
normal value of ≤ 5% (Chen et al., 2017). However, we know that uNK cells increase 
throughout the menstrual cycle (Russell et al., 2011; Russell et al., 2014; Russell et 
al., 2013) and it would be ideal to have a normal range of uNK cell density for each 
day of the menstrual cycle. Furthermore, to improve accuracy of testing, a UK 
consensus was reached and the test standardised for reliability and reproducibility 
across centres (Lash et al., 2016).  
When uNK cell density is above normal values, they appear to increase peri-
implantation angiogenesis which may lead to pregnancy failure due to excessive 
oxidative stress (Quenby & Farquharson, 2006; Quenby et al., 2009). In our research 
unit, recent work has shown that uNK cells are important in clearing senescent 
endometrial stromal cells to create spaces within the endometrium that supports 
implantation of an embryo (Brighton et al., 2017). An imbalance of senescent cells 
and uNK cells disrupts this process. 
It has been demonstrated that high uNK cell density can be reduced with 
prednisolone therapy (Quenby et al., 2005). In theory, reducing high uNK cell density 
would lead to increased rate of live births. However, the prognostic value on 
pregnancy outcome of treating high uNK cell density still remains uncertain (Dan et 
al., 2015; Tang et al., 2009; Tuckerman et al., 2007). This therapy also has significant 
adverse effects in pregnancy and it is not recommended outside a research setting. 
In addition, the test has the inherent error of interobserver variation and timing of 
the biopsy.  
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1.3.1 Normalisation for day of cycle 
 
Work in our research group has investigated improving the uNK cell density test by 
normalising for day of cycle when the endometrial biopsy was performed. This work 
was instigated because uNK cell density increases throughout the menstrual cycle. 
The normalisation heat-map was developed based on 1997 samples and this has 
recently been published (Brighton et al., 2017). To obtain confidence intervals, uNK 
cell density at each day of the cycle were fitted into a beta distribution with the 
‘fitdistr’ function from the MASS package version 7.3-45 (Venables & Ripley, 1997) 
in R version 3.2.1 (Team, 2015). The resulting percentile values were smoothed with 
spline interpolation using the spline function of the basic statistics package of R and 
converted into a heatmap using the Multi Experiment Viewer (MeV) version 4.9.0 
(Saeed et al., 2003). In this model, values above the 75th centile is high and above 
95th centile is very high. This is illustrated in Figure 1.10. 
 
Figure 1. 7: Graph of uNK centiles based on 1997 samples of women with recurrent 
reproductive failure. (Images courtesy of Pavle Vrljicak and Biomedical Research Unit in 
Reproductive Health, joint collaboration with University of Warwick and UHCW NHS Trust).  
This normogram shows uNK values increase as day of cycle progresses in the menstrual 
cycle. uNK values between 75th and 95th centile is high and above 95th centile is very high. 
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1.4 Combined endometrial factor predictive test 
 
Other groups have previously investigated combined endometrial tests. Recent 
work by Liu and colleagues, looked at combining the uNK density test with 
histological dating of endometrium to predict pregnancy outcomes (Liu et al., 2014). 
Their results show that uNK cell density on its own was not statistically significant in 
outcome prediction but histological dating improved this. Another group perform 
uterine immune profiling with uNK cell density and levels of activation or 
proliferation using markers of IL-15 and IL-18 to predict pregnancy outcome and 
form treatment strategies (Lédée et al., 2016; Lédée et al., 2017).  
Research from our group demonstrated that endometrial cell senescence increases 
during decidualisation. uNK cells have a role in clearing the senescent cells to form 
space within the endometrium to encourage implantation of an embryo. Therefore, 
it would be expected that senescence and uNK cell activity change together and can 
affect pregnancy outcome. On this basis, I aim to investigate a combined test of uNK 
cell density and cell cycle markers to evaluate its use as a predictor of subsequent 
pregnancy outcomes in women with RPL. 
 
1.5 Cell cycle markers 
 
I have reviewed the evidence of assessing decidualisation by histological findings 
using Noyes’ et al criteria. However, this does not describe the physiological 
processes during decidualisation.  This justified my investigation into the use of cell 
cycle markers. The markers of interest are that of proliferation Ki67 and senescence 
with loss of HMGB2 or presence of P16. I theorise that proliferation would be 
maximum in the proliferative phase but begin to decline in the luteal phase where 
senescence would become more dominant. Looking at this balance may identify 
endometrial mechanisms that are not synchronised or have abnormal timing.  
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Ki67 (Antigen KI-67) is a nuclear protein with a role in cellular proliferation and is 
associated with ribosomal RNA transcription (Shiozawa et al., 1996). It is present 
during all active phases of the cell cycle (G1, S, G2, and mitosis), but is absent from 
resting cells (G0). HMGB2 is the high-mobility group protein B2 which is part of the 
non-histone chromosomal high-mobility group protein family. The function of this is 
to promote DNA flexibility and repair. It maintains clonogenic populations in adult 
tissue. The loss of HMGB2 staining is a hallmark of replicative senescence and 
impaired decidualisation (Lucas et al., 2016). P16 is a cyclin-dependent kinase 
inhibitor 2A. It is a tumour suppressor protein. It decelerates cell progression from 
G1 phase to S phase. Increased expression of the p16 gene as organisms age reduces 
the proliferation of stem cells. This reduction in the division and production of stem 
cells protects against cancer while increasing the risks associated with cellular 
senescence as is seen in cervical neoplasia (Griffin et al., 2015). 
 
1.6 Hypotheses and objectives of project 
 
The objective of this research project is to develop and validate a pre-conceptual 
endometrial test that combines the endometrial cell cycle process and immune 
status to improve prediction of subsequent pregnancy outcome in women with 
recurrent pregnancy loss. I hypothesize that a pre-conceptual endometrial 
combined test would more accurately reflect the complexity of decidualisation, as it 
provides information about several processes that interplay to create a balanced 
microenvironment suitable for implantation. On this basis, I further hypothesize that 
this combined test would yield results that improves prediction of pregnancy 
outcome.  
I have chosen to use uNK cells as they are the key immune component and most 
abundant immune cell in relation to decidualisation. It also has an important role in 
vascular remodelling and clearing senescent cells in preparation for the implantation 
window. I will use cell cycle markers to explore the interplay between uNK cell 
activity and proliferative or senescence of endometrial stroma, glandular and 
65 
 
luminal cells. I will use the established method of the uNK cell density test and 
incorporate work within our research group that has looked at normalising uNK cell 
density for day of cycle (uNK centile). Following this, a combined test measuring cell 
proliferation and senescence using immunohistochemistry (IHC) cell cycle markers 
would be designed. 
As the first measure, I will assess the ability of the uNK cell density test in predicting 
pregnancy outcome in women with recurrent reproductive failure, to confirm or 
refute previous findings in the literature. I will then compare this to the predictive 
ability of the developed combined test and aim to validate the results in the setting 
of a prospective randomised-controlled trial.  
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MATERIALS AND METHODS 
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Chapter 2: Materials and methods 
2.1 Ethical Approval 
This research was supported by the Biomedical Research Unit in Reproductive 
Health; a collaboration between University Hospitals of Coventry and Warwickshire 
(UHCW) NHS Trust and the University of Warwick. The study was approved by the 
National Research Ethics – Hammersmith and Queen Charlotte’s & Chelsea Research 
Ethics Committee (1997/5065), West Midlands – South Birmingham Research Ethics 
Committee (15/WM/0295) and the local Research and Development department at 
UHCW NHS Trust. Written informed consent was obtained from the women who 
attended the clinic for research endometrial samples. The study period was between 
December 2011 and December 2017. 
 
2.2 Patient selection and pregnancy outcome database 
The research was completed through the tertiary referral Implantation Clinic, a 
dedicated endometrial research clinic at UHCW NHS Trust. Women with recurrent 
reproductive failure (RPL and RIF) attend this clinic from across the United Kingdom. 
All women have their medical history recorded by medical staff and is updated to a 
clinical database. The information includes details of previous pregnancy outcomes, 
fertility treatment and time to pregnancy interval. 
The clinical database is manually updated with future or ongoing pregnancy 
outcomes by investigators and relies on patient self-reporting of outcomes and local 
routine medical care. The subjects in this study were identified through this clinical 
database and a separate pregnancy outcome database was extracted from this 
information, based on pre-determined inclusion criteria. 
In the initial evaluation of the uNK test, I used the pregnancy outcome database and 
identified 281 women with RPL and RIF who had a pregnancy within one year of their 
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mid-luteal phase endometrial biopsy. These biopsies were obtained between 
December 2011 and October 2015. The two outcome measures of interest were first 
trimester miscarriage (M) and live birth or pregnancy beyond 10 weeks’ gestation 
(LB/O). 
Of these women, 20 were included in the exploratory test set to explore the 
association of cell cycle markers and pregnancy outcome. The associations found in 
the exploratory test set was used to design the pre-conceptual endometrial test in a 
larger study of 89 women. The criterion for the larger study were age under 40, 
history of recurrent pregnancy loss and biopsies taken between days 7 to 9 after LH 
surge. 
In the validation of the pre-conceptual endometrial test, I analysed 53 research 
endometrial samples that were collected through our local, pilot randomised-
controlled trial of ‘Scratch in Miscarriage’ (SiM). 
Finally, using the same clinical database mentioned previously, women who had two 
mid-luteal biopsies between one to six months apart and a pregnancy outcome 
within one year of the second biopsy were analysed. These biopsies were obtained 
between January 2016 and December 2017. 60 women who fit these criteria were 
identified and they included women with either recurrent pregnancy loss or 
implantation failure. This study sample of 60 women were analysed in this project 
to investigate the effect of endometrial biopsy or ‘scratch’ on uNK cell density and 
inter-cycle variation. 
 
2.3 Endometrial sampling 
In the Implantation Clinic, pre-conceptual mid-luteal phase endometrial biopsies 
were taken for the uNK cell density test and laboratory research. Written informed 
consent was obtained from women who attended the clinic after discussion of risk 
factors. The risk factors include vaginal spotting, vaginal bleeding and lower 
abdominal pain. 
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These biopsies were obtained using an endometrial sampler (Wallach Endocell TM 
sampler, Wallach Surgical Devices Inc., Trumbull, USA) and were timed at 6 to 12 
days after the LH surge.  The procedure was performed by first completing a 
transvaginal ultrasound scan to assess appropriate endometrial thickness and 
exclude uterine or endometrial pathology. A Cusco’s speculum was then used to 
visualise the cervix and a disposable endometrial sampler was inserted through the 
cervical canal into the uterine cavity. Drawing back on the inner piston creates a 
vacuum suction and an endometrial sample is obtained by withdrawing the sampler 
in a rotational technique from the uterine fundus. 
These endometrial samples are fixed in 10% neutral buffered formalin at 40C and 
processed by our research Arden Tissue Bank. Here, the samples are processed to 
create wax blocks which take 14 hours. In this procedure, tissue is dehydrated 
through a series of graded ethanol baths to displace the water, and then infiltrated 
with paraffin wax. The infiltrated tissues are then embedded into wax blocks. Once 
the tissue is embedded, it is stable for many years allowing storage of tissue for 
further research.   
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2.4 Immunohistochemistry 
2.4.1 Materials 
1. Adhesive microscope slides - Leica Xtra® adhesive slides, Leica 
Biosystems (UK) Ltd, Milton Keynes, UK 
2. Distilled water 
3. Hematoxylin (<0.1%) - Leica Biosystems (UK) Ltd, Milton Keynes, UK 
4. Isopropyl Alcohol 
5. Phosphate buffered solution (PBS) 
6. Primary antibody – 1:200 dilution (Novocastra™ Mouse Monoclonal antibody 
NCL-L-CD56-504) - Leica Biosystems (UK) Ltd, Milton Keynes, UK 
7. Primary antibody – 1:5 dilution (CINtec® clone E6H4 p16Ink4a antibody) - 
Roche, Basel, Switzerland 
8. Primary antibody – 1:500 dilution (HMGB2) 
9. Primary antibody – 1:200 dilution (Ki67) 
10. Sodium citrate buffer; 10mM sodium citrate, 0.05% Tween-20, pH 9 - Leica Biosystems 
(UK) Ltd, Milton Keynes, UK 
11. Tris-buffered saline plus 0.05% tween20 (TBST) 
12. Xylene 
13. 3% (v/v) hydrogen peroxide - Leica Peroxidase Block, Leica Biosystems 
(UK) Ltd, Milton Keynes, UK 
14. 3, 3’ – diaminobenzedine (DAB)  
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2.4.2 Slide preparation and staining 
 
The tissue wax blocks of identified subjects for cell cycle analysis were obtained from 
the Research Arden Tissue Bank. Each wax blocks were sliced into 3µm thick sections 
on a microtome. An experienced operator performed the sectioning to achieve 10 
accurate serial tissue sections. The tissue sections were adhered to microscope 
coverslips by overnight incubation at 60°C. For each subject, one of the serial 
sections were stained using immunohistochemistry (IHC) with antibodies for 
markers of CD56 (uNK), p16 and HMGB2 (cell senescence) and Ki67 (cell 
proliferation).  
Each antibody is made with the following dilution: CD56 1:200, Ki67 1:200, HMGB2 
1:500 and p16 1:5. 30 slides are run within one cycle on the Leica Bondmax 
autostainer. In each cycle, 5 patients’ samples were processed which included 4 IHC 
antibody stains per patient and 1 control slide per antibody. The IHC protocol used 
can be found in Figure 2.1. 
The immunohistochemistry staining was performed using an automated process 
with the Leica Bondmax autostainer (Leica Biosystems) and a dedicated research 
technician performed this step. This automated process begins with de-waxing the 
paraffin sections using xylene and rehydration. Antigen retrieval is performed with 
sodium citrate antigen retrieval solution (sodium citrate buffer; 10mM sodium 
citrate, 0.05% Tween-20, pH 9) to make epitomes clear. Hydrogen peroxide follows 
to halt peroxidase activity while binding and removing blood cells. The tissue 
sections are then ready for staining with required antibodies (CD56, p16, HMGB2 
and Ki67). The process is completed with DAB colour development and 
Haematoxylin counter stain. The dehydrated and cleared coverslip sections are 
processed through the Mirax Midi slide scanner, to obtain bright-field images which 
were analysed using Pannoramic Viewer v1.15.4 (3DHISTECH Ltd, Budapest, 
Hungary) software. 
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Immunohistochemistry process 
 
 
E.g. CD56 
 
Time Process 
 
14 hours 
A. Preparing to wax block 
Formalin (fix)       Alcohol (dehydrate)       Xylene (attach 
wax)       Wax Block 
 Slicing wax block to 3 micrometres onto slide 
3 hours 
(1 cycle; 
30 slides) 
B. Leica machine 
Reverse process to wash off wax and rehydrate 
Buffers used to make epitome clearer 
Peroxide used to bind and remove blood 
Custom antibody to CD56 (mouse) 
Add human antibody to mouse labelled H-DAB  
Haematoxylin stain (H&E) 
Batch control – negative CD56 and positive control small 
bowel  
 Covered with plastic film and then scanned into a MIRAX 
file 
 
Figure 2. 1: IHC protocol. A. Process of preparing tissue wax block. B. Automated IHC 
staining process using the Leica Bondmax Machine and MIRAX scanner. The flowchart 
above demonstrates the IHC protocol used in this research project. 
 
The tissue blocks obtained from the research tissue bank had previously undergone 
14 hours of processing to create the wax block. Serial sectioning was performed on 
the tissue blocks to allow for the 4 different antibody stains (CD56, HMGB2, p16, 
Ki67). In the above example using CD56 antibody staining, the IHC process for 30 
slides per cycle was completed in 3 hours. The principal of IHC is removing wax and 
rehydrating slide, buffering to make epitomes clearer, remove blood with peroxide, 
apply custom antibody then human antibody labelled H-DAB, followed by 
haematoxylin staining. Batch controls are used for quality control in each cycle.  
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2.4.3 Analysis and interpretation 
IHC staining analysis 
The MIRAX files created are opened using Pannoramic Viewer software in wide-
screen view. Each patient file contains an image of CD56, p16, HMGB2 and Ki67 IHC 
stain. Within the Pannoramic viewer software, the 3 matched sites at 20x 
magnification for each IHC stain is captured and saved as a Tiff file. Therefore, each 
patient would have 12 Tiff files which are then processed in Image J software 
(Rasband W.S. ImageJ, National Institutes of Health).  
The sites that are chosen must include an epithelial lining as it standardises the 
depth of tissue for analysis. This avoids inconsistencies in the densities of IHC 
markers measured. The 3 equal sites for each IHC stain (CD56, HMGB2, p16, Ki67) is 
used to obtain an average value for the whole sample. Figure 2.2 and 2.3 illustrates 
these processes. 
   
Figure 2. 2: MIRAX file in Pannoramic Viewer software. Low power magnification of a 
tissue section stained with CD56 showing how three representative areas would be chosen 
for analysis at higher magnification.  
 
The above image is an example of a stained section for CD56 marker. Within each 
MIRAX file 3 areas are selected to calculate the average density of IHC marker for 
the corresponding sectioned slide. 
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Figure 2. 3: Serial sections of (a) HMGB2 (b) CD56 (c) Ki67 and (d) p16 antibody staining 
from the same patient biopsy. This diagram illustrates the similar areas within the tissue 
sample that can be identified using serial sectioning. 
 
Serial sections of 3 micrometres thickness were performed by experienced 
technicians to obtain slides with similar image to allow good comparisons across the 
four IHC markers used (CD56, p16, HMGB2 and Ki67). 
 
Cell cycle marker density 
In order to calculate the density of IHC stain of custom antibody for each image 
created by the IHC protocol in Figure 2.2 and 2.3, I initially used cell counter in Image 
J and overlaid each image to identify which cells showed cell senescence or 
proliferation. However, this process was laborious and time-consuming. The 
accuracy of this method was more reliant on the quality of serial sectioned images. 
Due to the difficulty of consistently producing top quality serial sectioned images 
and feasibility of running a predictive test in large numbers with processes that are 
time-consuming, I decided to use the recognised, standardised method now used in 
uNK cell density tests (Drury et al., 2011; Drury et al., 2013; Lash et al., 2016).  
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This standardised method used colour de-convolution and thresholding technique 
in Image J software. Colour de-convolution using Image J Plugin splits the image into 
single colour channels of brown (e.g. CD56+ staining) and blue (haematoxylin cell 
nucleus staining) (Ruifrok & Johnston, 2001) as seen in Figure 2.4. Next, we use the 
thresholding function in Image J to set the level of staining against background 
threshold (Figure 2.4). The separated images in the 2 colour channels allow the 
colour intensity of the antibody over background endometrial stromal cells to be 
calculated and provide percentage of density of antibody marker within image. For 
example, the uNK percentage from these data were calculated as CD56 / stromal 
cells × 100 (Drury et al., 2013). The average of 3 sites per patient and antibody is 
used to represent density in each corresponding endometrial section slide. 
Localisation 
Looking at areas of interest within a sample requires manually generating separate 
images of the endometrial stroma, lumen and glands for each IHC stained marker 
per patient (Figure 2.5). The protocol established in Figure 2.1 to 2.5 are repeated 
and the average of 3 sites is calculated. 
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Figure 2. 4: Colour de-convolution and thresholding technique. Each Tiff file (20x 
magnification) of an area within a sectioned slide underwent colour de-convolution then 
thresholding to calculate the percentage of density within the selected area. An average of 
3 selected areas is calculated for each IHC marker. 
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Figure 2. 5: Generating separate images to determine localisation of IHC markers. Average 
values for each IHC marker localised for the endometrial stroma, gland and lumen can be 
calculated. 
 
 
The above figure illustrates how each image of a selected area can be edited in 
Image J to generate separate images of localised areas (luminal, glandular and 
stromal layer). This allows comparison of IHC markers within prescribed areas of 
interest. Each separate image underwent colour de-convolution and thresholding 
technique to measure IHC marker density. 
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2.5 Statistical Analysis 
Data from the pregnancy outcome database were analysed with IBM® SPSS® 
Statistics V22.0 statistical software. Binary logistic regression and chi-squared test 
was used. I also formulated a receiver operating characteristic (ROC) curve to 
validate the predictive ability of the developed combined pre-conceptual 
endometrial test.  
Data in the combined test were analysed with GraphPad Prism 6 (GraphPad 
Software Inc.). Mann-Whitney U test and Kruskal-Wallis test was performed where 
appropriate. Data in the inter-cycle variation tests were analysed using this 
software. Wilcoxon test was performed to compare the paired biopsy values.  
Statistical significance was reached when P < 0.05.  
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EVALUATION OF uNK TEST AS 
PREDICTOR OF OUTCOME 
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Chapter 3: Evaluation of uNK cell test as 
predictor of outcome 
3.1 Background 
As discussed in my introduction chapter, the uNK cell density has been shown to be 
high in recurrent reproductive failure. Research on the prognostic ability of uNK cell 
density test has been inconclusive. Here, I tested the hypothesis that uNK cell 
density test has the ability to predict subsequent pregnancy outcome in women with 
recurrent pregnancy loss or recurrent implantation failure. This test was repeated 
for the locally developed uNK centile test to investigate whether normalising the 
uNK cell density for day of cycle, increases accuracy and predictive ability of the test. 
 
3.1.1 Hypothesis 
In the uNK cell density test, a result of 5% or more was classified as high based on 
previous research (Chen et al., 2017; Quenby et al., 1999; Quenby et al., 2005; Tang 
et al., 2011; Tang et al., 2013). In the uNK centile test, a result on the 75th centile or 
above was classified as high for the purpose of this study (Brighton et al., 2017). 
Therefore, my hypothesis is women with a high uNK cell density are less likely to 
have a live birth or pregnancy beyond 10 weeks. My second hypothesis is the uNK 
centile would be more accurate than uNK cell density in predicting women who are 
less likely to have a live birth or ongoing pregnancy. 
 
3.1.2 Methods 
This was a retrospective cohort study. I collated data on 281 women who fulfilled 
the criteria of history of recurrent reproductive failure and a recorded pregnancy 
event within one year of their mid-luteal endometrial biopsy. The primary outcome 
of interest was pregnancy outcome, which was divided into two groups; live birth or 
ongoing pregnancy beyond 10 weeks gestation and first trimester miscarriage.  
81 
 
The demographic details analysed and investigated as confounding factors included 
age, parity, presence of subfertility and previous pregnancy losses. I was unable to 
assess body mass index (BMI) as a confounder as this was not recorded in a large 
proportion of this study sample.  
I processed the 281 women’s data using binary logistic regression to address the 
effect of confounding factors on the calculated probability in the above statistical 
tests. This will assess the adjusted odds ratio of live birth or pregnancy beyond 10 
weeks using the uNK cell density and uNK centile test. 
 
3.2 Results 
3.2.1 Demographics 
Demographic details; n=281 
 
Table 3. 1: Demographic details in uNK evaluation test. Distribution of maternal age, uNK 
cell test, previous history of miscarriages, parity and fertility in the study sample is 
demonstrated above and compared in each pregnancy outcome group; (i) live birth or 
ongoing pregnancy beyond 10 weeks gestation and (ii) miscarriage. 
 
In evaluating the uNK cell density test, a total of 281 women were identified 
retrospectively from the Implantation Clinic’s clinical database. The demographic 
information for this cohort study is found in Table 3.1. The women were divided into 
two groups based on the primary outcome of interest (Group 1 – live birth or 
ongoing pregnancy beyond 10 weeks gestation and Group 2 – first trimester 
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miscarriage). A normality test was performed and data for uNK cell density, uNK 
centile, previous history of miscarriages, parity and fertility did not follow a normal 
distribution (Shapiro-Wilk test). 
In this study, 185 (65.8%) women were successful in achieving a live birth or a 
pregnancy beyond 10 weeks gestation. There was no significant difference in age 
(p=0.089), parity (p=0.886) and fertility (p=0.644) in Group 1 and Group 2. The mean 
age of all subjects was 34.8 (±4.28), 202 (71.9%) women were nulliparous, 163 (58%) 
women had history of RPL and 118 (42%) women had subfertility. 
The most significant difference between the two groups was number of previous 
miscarriages with a median of 4 (IQR 2-5) in the miscarriage group compared the 
median of 3 (IQR 2-4) in the live birth or ongoing pregnancy beyond 10 weeks group 
(p=0.005).  
In this demographic data, the uNK test was assessed without use of cut off value for 
a high result to investigate the distribution between the two groups. There was a 
significant difference in uNK cell density (p=0.017) in the two groups with median of 
4.78% (IQR 2.5-8.33%) in Group 1 and median of 6.75% (IQR 2.87-11.99%) in Group 
2. In contrast, the uNK centile test was not significant (p=0.05) with median 46.5 
centile (IQR 18-70.5) in Group 1 and median 53.8 centile (IQR 27.8-75.9). 
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3.2.2 The uNK cell density test and its predictive ability 
 
Table 3. 2: Binary logistic regression to investigate ability of uNK cell density test to predict 
pregnancy outcome. Confounding factors included in the test were maternal age, number 
of previous miscarriages, parity and fertility. The only significant factor in predicting 
pregnancy outcome was 5 or more previous miscarriages (p=0.005). 
 
To test the hypothesis that women with a high uNK cell density test are less likely to 
have a live birth or ongoing pregnancy beyond 10 weeks gestation, I conducted a 
binary logistic regression on all demographic data collected to account for 
confounding factors. I divided the data describing the number of previous 
miscarriages into three binned groups (<2 miscarriages, 3-4 miscarriages and ≥ 5 
miscarriages) as this provides information on severity of phenotypic presentation.  
Results were expressed as [odds ratio (OR); 95% confidence interval (CI); P value]. 
The uNK density cut off value of 5% was used, where a high value was ≥ 5%.  
This regression analysis showed that uNK cell density test was not a good predictor 
of outcome in subsequent pregnancy [adjusted OR: 0.65; 95% CI: (0.39 – 1.09); 
p=0.1] (Tab. 3.2). Number of previous miscarriages was the only significant predictor 
of outcome when there were 5 or more miscarriages [OR: 0.27; 95% CI: (0.11 – 0.67); 
p=0.005]. Factors such as age, parity and fertility did not appear to effect outcome 
prediction. 
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3.2.3 Normalising the uNK cell density test to improve its 
predictive ability 
It has been shown that uNK cell density gradually rises in the secretory phase of the 
menstrual cycle (Johnson et al., 1999; Loke & King, 2000c; Vince & Johnson, 2000).  
This suggests that a single cut off value of 5% may not effectively identify women 
with poorer outcomes and supports the findings in this cohort study. The uNK centile 
test normalises for day of the cycle the biopsy was taken. Therefore, it is 
hypothesised that the uNK centile test is more accurate and would predict 
subsequent pregnancy outcome better. For the purpose of this cohort study, a high 
uNK centile was a value of ≥ 75th centile. 
The binary logistic regression was repeated substituting uNK cell density with the 
corresponding uNK centile value. Results were expressed as [odds ratio (OR); 95% 
confidence interval (CI); P value].  
 
 
Table 3. 3: Binary logistic regression to investigate ability of uNK centile test to predict 
pregnancy outcome. The same confounding factors as used to evaluate the uNK density 
test were included in this test. The only significant factor in predicting pregnancy outcome 
after adjustment was 5 or more previous miscarriages (p=0.006). However, the unadjusted 
value for uNK centile was significant (p=0.04) suggesting that it is a marginally better 
prognostic test than uNK density. 
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The analysis showed that the uNK centile was significant as a predictor of live birth 
or ongoing pregnancy prior to adjustment for confounding factors [OR: 0.53; 95% CI: 
(0.29 – 0.97); p=0.04]. The significance level was lost when adjusted for confounding 
factors [adjusted OR: 0.53; 95% CI: (0.28 – 1.00); p=0.05] (Tab. 3.3). However, it did 
perform better than the uNK cell density test [adjusted OR: 0.65; 95% CI: (0.39 – 
1.09); p=0.1]. As seen in the first logistic regression analysis, the only significant 
predictor was number of previous miscarriages when there were 5 or more 
miscarriages [OR: 0.28; 95% CI: (0.12 – 0.69); p=0.005]. 
 
3.2.4 uNK test in Recurrent Pregnancy Loss 
My research is aimed to design an endometrial test for women with recurrent 
pregnancy loss. Therefore, I have extracted the data on women without subfertility 
issues from this database. There are 163 women with ‘RPL only’ in this study 
sample. I have repeated the binary logistic regression for these women to ascertain 
whether there is any difference in the results. The following tables illustrate the 
predictive ability of uNK density and uNK centile test in women with ‘RPL only’. 
 
 
Table 3. 4: Binary logistic regression to investigate predictive ability of the uNK test in 
women with RPL only. The data shows that both the uNK density is unable to predict 
pregnancy outcome in this group of women. 
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Table 3. 5: Binary logistic regression to investigate predictive ability of the uNK test in 
women with RPL only. The data shows that both the uNK centile is unable to predict 
pregnancy outcome in this group of women. 
 
The statistical analyses show that the uNK density and uNK centile test are unable 
to predict pregnancy outcome in women with RPL. The odds ratios are [OR: 1.05; 
95% CI: (0.53 – 2.07); p=0.90] and [OR: 0.92; 95% CI: (0.37 – 2.29); p=0.86] 
respectively. There was no difference between the uNK density or uNK centile test. 
It also confirms that number of previous miscarriages is the only significant factor 
in pregnancy outcome prediction in this study. 
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3.3 Discussion 
3.3.1 Limitations 
The limitations of this cohort study can be divided into data collection and inherent 
error of the uNK test. Bias is introduced during data collection as it is a retrospective 
study and the recording of pregnancy outcomes are reliant on patient reporting. 
Some of these women would have also received medical intervention in the form of 
progesterone and glucocorticoid therapy.  
Over the five-year duration of this study, the uNK cell density test has been 
calculated by multiple investigators and the method of calculation changed from a 
counting method using point picker to image analysis using Image J software. The 
counting method is more accurate but time consuming. Therefore, it is not an 
efficient method to process large number of samples. The image analysis is 
calculated on the area of CD56 which is a uNK cell surface marker over the area of 
the stromal nuclear marker (haematoxylin staining). The known test intra-observer 
error in image analysis is about 20% as analysed in our laboratory. In the uNK centile 
test, there is an added error of patient reported ovulation tests which can be 
reported imprecisely by women. 
 
3.3.2 Conclusions 
The strength of this cohort study is the large sample size. The results show that the 
uNK cell density test is not a good prognostic test of subsequent pregnancy 
outcome.  
The uNK centile calculation more than halved the women with a high uNK test value 
in comparison to the uNK cell density test in the whole recurrent reproductive failure 
dataset (n=54 and n=137 respectively). However, the uNK density and uNK centile 
tests are unable to predict pregnancy outcome in women with recurrent 
reproductive failure.  
88 
 
It is clear that the number of previous miscarriages is the only significant factor that 
predicts pregnancy outcome in this study. These findings support previous evidence 
that history of miscarriages is a good predictor of subsequent pregnancy outcome. 
However, this does not assist in managing most women with recurrent reproductive 
failure because it is not modifiable.  
Recent scientific advances in the physiology of decidualisation would suggest a 
complex system with interplay of several components that when balanced, supports 
a karyotypically normal embryo. These components include cell senescence and 
mesenchymal stem cells (Lucas et al., 2016). In my research, I proceeded to explore 
biomarkers for cell cycle proliferation and senescence in the mid-luteal phase 
endometrium and focused on women with recurrent pregnancy loss. I investigated 
whether knowledge gained could improve the predictive ability of the uNK test by 
combining multiple factors that constitute decidualisation. 
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EXPLORATORY TEST SET FOR 
PREDICTOR MARKERS  
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Chapter 4: Exploratory test set for predictor 
markers 
4.1 Background 
In this research, I have concentrated on exploring a predictive model for subsequent 
pregnancy outcome in women with recurrent pregnancy loss. The premise for this 
model is a combined pre-conceptual endometrial test incorporating multiple factors 
within the endometrium that are important for decidualisation and enabling support 
of normal karyotypic embryos. 
The uNK cell test has been adopted widely (Quenby and colleagues in UK, Sacks and 
colleagues in Australia, Li and colleagues in Hong Kong) because; 
1. uNK cells have consistently been found to be higher in reproductive failure 
(Quenby et al., 1999; Tuckerman et al., 2007) 
2. uNK cell density correlates negatively with markers of decidualisation  
(Kuroda et al., 2013) 
3. uNK cell density has been used as a marker of local cortisol deficiency  
(Kuroda et al., 2013) 
4. uNK cell density test has been used to identify women who may benefit from 
steroid to prevent repeated pregnancy loss (Tang et al., 2011) 
However, the test has limitations as described in previous chapters. 
Decidualisation involves a number of processes as well as uNK cell infiltration. 
Recent findings within our biomedical research unit has shown that impaired 
decidualisation is associated with recurrent pregnancy loss due to accelerated 
senescence and loss of endometrial mesenchymal stem cells (eMSCs) as it limits 
differentiation capacity of the endometrium (Lucas et al., 2016). It was found that 
knockdown of the chromatin protein HMGB2 (high mobility group protein 2) in 
human endometrial stromal cells (HESCs) promotes senescence and impairs 
decidualisation.  
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Other researchers have investigated the possibility of tests to predict subsequent 
pregnancy outcomes. LéDée and colleagues have shown that immune profiling of 
uNK cell density by investigating the activity and proliferation of uNK cell improves 
prognostic ability of the uNK test (Lédée et al., 2016; Lédée et al., 2017). Research 
by Li and colleagues, also found that histological dating of endometrium improves 
prognostic ability of the uNK cell density test (Liu et al., 2014). Histological dating 
includes assessment of the development of glands and spiral arteries in the 
decidualisation process. 
We aimed to improve the uNK test by combining it with biomarkers of proliferation 
and senescence to the stroma, glands and lumen of the endometrium. We also 
aimed to explore the importance of these components as separate entities. 
Immunohistochemistry was used to detect biomarkers of uNK cells (CD56), cell 
proliferation (Ki67) and cell senescence (HMGB2 and p16). 
Considering all these factors, the following hypotheses were developed. 
 
4.1.1 Hypotheses 
1. Reduced proliferation indicated by low Ki67 activity in human endometrial 
stromal, luminal or glandular cells is associated with recurrent pregnancy loss 
2. Increased ratio of proliferation indicated by Ki67 in uNK cells indicates active 
uNK cells and is associated with recurrent pregnancy loss  
3. Increased senescence indicated by raised p16 and loss of HMGB2 in human 
endometrial stromal, luminal or glandular cells is associated with recurrent 
pregnancy loss 
4. A balance of endometrial cell proliferation and senescence support 
decidualisation and improves chance of supporting an embryo leading to a 
live birth 
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4.1.2 Methods 
This study is an exploratory test using cell cycle biomarkers to design a predictive 
model of subsequent pregnancy outcome in women with recurrent pregnancy loss. 
In order to improve the uNK cell test, I selected an exploratory test set which 
consisted of women attending our ‘Implantation Clinic’. I included women with 
recurrent pregnancy loss, a biopsy between LH + 6 to 10 days and known pregnancy 
outcome within one year of their biopsy (n=20). This exploratory study took place 
prior to the development of uNK centile. Therefore, a normal uNK cell density was 
defined as below 5% in this test set. I pre-defined 4 groups and identified 5 women 
into each group. The groups were defined as: 
 
A: High uNK cell density and subsequent live birth (uNK false positive test) 
B: High uNK cell density and subsequent miscarriage (uNK true positive test) 
C: Normal uNK cell density and subsequent live birth (uNK true negative test) 
D: Normal uNK cell density and subsequent miscarriage (uNK false negative test) 
 
This exploratory set was devised to include women who had a further miscarriage 
and a more severe phenotype to make any difference between the groups more 
pronounced to enable detection. Each patient’s history and pregnancy outcome are 
reported in Table 4.1. 
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Table 4. 1: Demographic details in exploratory test set. Women with more severe 
phenotype were chosen for this test set to enable detection of differences between groups. 
Group A denotes the false positive uNK test, Group B the true positive uNK test, Group C 
the true negative uNK test and Group D the false negative uNK test. 
 
All endometrial samples underwent the same immunohistochemistry (IHC) process 
as outlined in chapter 2. The MIRAX files created were analysed using Pannoramic 
Viewer and Image J software. The identified cell cycle markers used for this 
exploratory analysis were CD56 (uNK), HMGB2 and p16 (cell senescence) and Ki67 
(cell proliferation). We compared the trend of each cell cycle marker in the 4 defined 
groups to determine whether an association exists between density of cell cycle 
markers, it’s localisation within the endometrium and pregnancy outcome. 
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4.2 Results 
4.2.1 Proliferative and senescent cell ratio 
In the early stages of this exploratory study, I used a cell counting and image stacking 
method in Image J software, to identify single cells and corresponding IHC markers 
of interest. I describe the cell counting method below. This method is reliant on good 
serial sections to identify the same cell for each IHC marker and is time-consuming. 
Hence, after the initial results in this chapter, I adopted the method of thresholding 
and localisation as described in Chapter 2.  
Methods of cell counting 
1. Each patient had four images in TIFF file with IHC staining for CD56, Ki67, 
HMGB2 and p16. 
2. The images of CD 56, Ki67 and p16 staining were overlain using image stacker 
and grid to allow identification of single cells on the corresponding IHC serial 
section. This helps identify whether a uNK cell (CD56) or stromal cell 
(haematoxylin) is senescent (p16) or proliferative (Ki67).  
3. The cell counter is then used to count the total number of uNK cells (CD56), 
the stromal cells (haematoxylin) and the corresponding uNK and stromal 
cells that are proliferative (CD56Ki67+ and stromalKi67+) or senescent (CD56p16+ 
and stromalp16+). 
4. The following formula was used to calculate ratio of proliferative uNK cells, 
ratio of senescent uNK cells, ratio of proliferative stromal cells and ratio of 
senescent stromal cells. 
o [(uNKKi67+)/all uNK cells]*100 
o [(uNKp16+)/all uNK cells]*100 
o [(stromalKi67+)/all stromal cells]*100 
o [(stromalp16+)/all stromal cells]*100 
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5. HMGB2 staining was assessed separately to calculate the loss of the marker 
as sign of senescence [(HMGB2 loss/all stromal cells] *100. 
  
 
 
 
 
 
 
 
Figure 4. 1: An example of serial section from a patient used in image stack and cell 
counting to calculate proliferative and senescent uNK cells. A) CD56 stained slide B) Ki67 
stained slide C) p16 stained slide. The blue grid was used to align the image on top of each 
other so that I could identify which CD 56 cells were also Ki67 or p16 positive. 
 
Figure 4. 2: An example of serial section from a patient used in image stack and cell 
counting to calculate proliferative and senescent stromal cells. A) Ki67 stained slide B) p16 
stained slide C) HMGB2 stained slide D) Counted stromal cells 
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The results showed no significant difference in proliferative or senescent uNK cell 
ratios in the four groups; as shown in Figure 4.3.  
There was significance in the difference of proliferative and senescent stromal cells 
across the groups (Figure 4.4). However, the difference did not discriminate 
between pregnancy outcomes. Higher levels of stromal proliferation and 
senescence are present when uNK cell density is high. Therefore, it does not add 
value to the uNK test.  
In addition, HMGB2 loss in stromal cells did not significantly differentiate between 
the groups (Figure 4.5). 
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Figure 4. 5: Comparison of loss of HMGB2 in stromal cells between the 4 pre-determined 
groups. This graph measures stromal senescence using HMGB2 loss in stromal cells as a 
proportion of total stromal cell within sample image used. There was no significant 
difference between the groups (Kruskal-Wallis test). 
 
4.2.2 Localisation of proliferation and senescence in stromal, 
glandular and luminal cells. 
 
The colour de-convolution and thresholding technique described in Chapter 2 was 
used for the localisation of cell proliferation and senescence test. The results are 
shown in Figures 4.6 to 4.9. 
Proliferation in the stroma, glandular and luminal cells were not significantly 
different between the four groups. Interestingly, stromal proliferation appeared to 
be high when uNK cell density were high.  
Stromal senescence measured by HMGB2 loss and p16 levels were also not 
significant.  
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However, HMGB2 levels reached statistically significant levels when comparing the 
four groups in the glandular and luminal cells (p=0.04 and p=0.03 respectively) 
(Figure 4.7). P16 levels were also significantly different across the groups in the 
glandular and luminal cells (p=0.02 and p=0.03 respectively) (Figure 4.8). 
Further analysis, showed that raised glandular and luminal p16 levels in the presence 
of high uNK cell density were associated with further pregnancy loss (p=0.02 and 
p=0.03 respectively) (Figure 4.8).  However, only HMGB2 loss in the lumen 
differentiated the groups by pregnancy outcome data irrespective of uNK cell 
density (p=0.003) (Figure 4.9). It was found that HMGB2 loss in the lumen was 
associated with further pregnancy loss. 
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Figure 4. 9: Endometrial cell senescence and pregnancy outcome. I performed Mann-
Whitney test on the significant results in Figure 4.7 and 4.8 to investigate whether the tests 
can discriminate based on pregnancy outcome irrespective of uNK result. The graphs 
illustrate A) HMGB2 loss in glandular cells, B) HMGB2 loss in luminal cells, C) p16 presence 
in glandular cells and D) p16 presence in luminal cells. HMGB2 loss in luminal cells was the 
only significant factor in association with further pregnancy loss irrespective of uNK result. 
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4.3 Discussion 
 
This exploratory data set was useful. It looked to test the hypotheses generated prior 
to the study.  
 Proliferative markers 
 
The study tested whether the ratio of CD56 or stromal cells stained with Ki67, a 
proliferative marker, would predict pregnancy outcome. The results showed that 
cell proliferation using Ki67 did not add significant information to uNK cell density 
test as suggested by LéDée and colleagues (Lédée et al., 2016; Lédée et al., 2017). It 
must be noted that I have used a different method to measure uNK proliferation and 
it is likely to be a less accurate way of measuring this. Although we used a small 
number of patients, this method was time-consuming and thousands of cells were 
counted. We should have been able to detect big differences in the Ki67 positive 
cells but did not find this. Therefore, the study did not support Hypothesis 1 or 2. 
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 Senescent Markers 
 
 
In the effort to test Hypothesis 3 and 4, I found a combination of positive and 
negative results dependent on localisation of the marker to the lumen, gland or 
stroma. The findings are summarised below: 
 Glandular p16 marker appeared to identify women with high uNK density 
and subsequent miscarriage 
 Stromal p16 and Ki67 ratios varied in the same manner as the uNK density 
 HMGB2 loss in lumen appeared to identify women with a subsequent 
miscarriage irrespective of uNK density 
 
The cell senescence marker in the glands (glandular p16), was found to help 
differentiate false positive test from true positive test. Senescence (p16) was higher 
in the glands of women with true positive test (high uNK and subsequent 
miscarriage) compared to the false positive test (high NK and subsequent live birth). 
We hypothesize that the natural progression of endometrial glandular development 
is due to senescence, denoting cell maturation, after the mid-luteal phase peak 
differentiation. This finding supports that of Liu and colleagues, who suggest that 
glandular development identified using histological Noyes criteria improved the uNK 
test. We hoped that using IHC would be more objective than pathologist subjective 
histological dating (Coutifaris et al., 2004; Lessey et al., 2000; Myers et al., 2004).  
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Interestingly, stromal p16 senescent marker and Ki67 proliferative marker ratios 
varied in the same manner as the uNK density.  The reason of this is elucidated in a 
further publication describing a role for uNK cells in clearing senescent cells 
(Brighton et al., 2017). These new findings mean that uNK cell density will reflect 
stromal senescence.  Further work suggested that clearing senescent cells leads to 
stimulation of stem cells and proliferation that could have been detected with Ki67 
(Brighton et al., 2017). Other work in our laboratory, had suggested that impaired 
stromal senescence would be useful in predicting outcome but I found no evidence 
to support this in the exploratory test set (Lucas et al., 2016).  
HMGB2 was also found to be lower in the luminal layer in those with a miscarriage 
irrespective of the uNK cell test result.  This addition of a luminal compartment layer 
has never been explored before. However, in terms of technicality of the test, a 
glandular test is easier to calculate than a luminal one as it can be difficult to find a 
good length of intact luminal tissue due to the endometrial sampling process 
The limitation of this study is that it is a retrospective study and this introduces bias 
in data collection. Another confounding factor is that the proportion of miscarriages 
due to chromosomal abnormality is unknown. Therefore, the results need to be 
tested on a larger scale to confirm the hypothetical association of senescent markers 
and subsequent pregnancy outcomes. Finally, the findings of the larger study would 
need to be evaluated in a prospective study setting to reduce bias.   
Based on the results of this exploratory study, I have selected p16 and HMBG2 in the 
glands and lumen for further development in a larger study sample of 89 women. 
The aim would be to validate the resulting combined pre-conceptual endometrial 
test in a prospective RCT setting.  
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Chapter 5: ‘Combined pre-conceptual 
endometrial test’ development study 
 
5.1: Background 
It was found in the exploratory test set, that loss of HMGB2 in endometrial luminal 
layer and increased P16 with high CD56 in endometrial glandular layer appear 
associated with a subsequent pregnancy loss. I designed a study protocol to test the 
validity of the hypotheses made. I aim to develop a pre-conceptual endometrial test 
using knowledge gained and assess its ability to improve prediction of subsequent 
pregnancy outcome of the uNK test. 
 
5.1.1 Testing hypotheses 
The hypotheses tested are; 
1. Endometrial luminal senescence (HMGB2) is associated with further 
pregnancy loss despite uNK cell density 
2. Mature glandular development indicated by increase endometrial glandular 
senescence (p16), when associated with high uNK cell density is associated 
with further pregnancy loss 
3. Endometrial stromal senescence does not predict subsequent pregnancy 
outcome 
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5.1.2 Methods 
 
In this study protocol, a systematic approach of investigating cell senescence in each 
localised area of the endometrial stroma, glands and lumen was used. IHC staining 
was performed for HMGB2 and p16 on serial sections of each area mentioned and I 
explored associations with respective uNK cell density and subsequent pregnancy 
outcomes.  
In order to establish this study, I identified a larger retrospective study sample of 89 
patients with age under 40, recurrent pregnancy loss, an endometrial biopsy taken 
at LH +7 to +9 and a pregnancy event within 1 year of their biopsy. Each IHC stained 
serial section was processed using localisation, colour de-convolution and 
thresholding technique in Image J software as described in Chapter 2.  
 
The study sample was derived from two groups: 
1. Subsequent live birth or ongoing pregnancy beyond 10 weeks (LB/O) 
2. Subsequent first trimester miscarriage (M) 
 
Recent work in our research laboratory has formulated the uNK centile heat-map 
which represents the uNK density normalised for day of cycle the endometrial biopsy 
was taken and is based on 1997 samples. I have discussed the uNK centile values in 
more depth in Chapter 1. In this study, I have adopted the uNK centile due to the 
increased accuracy of uNK activity based on timing of biopsies.  
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5.2 Results 
5.2.1 Demographic data 
 
In this study, I developed a pre-conceptual endometrial test based on 89 women with 
recurrent pregnancy loss fulfilling the criteria stated above. 44 women had a live birth or 
ongoing pregnancy beyond 10 weeks gestation following their endometrial biopsy and 45 
women had a further miscarriage. These two groups did not differ in maternal age or parity 
but there was a significant difference in the number of previous miscarriages. Women with 
a further miscarriage had a median of four miscarriages and those who had a positive 
pregnancy outcome had a median of 3 (p= 0.02; Mann-Whitney U test). 
 
 PREGNANCY 
BEYOND 10 WEEKS 
N= 44 
MISCARRIAGE                 
 N= 45 
P VALUE 
AGE, MEAN (SD) 34 (4.1) 33 (3.3) 0.44 
NO OF PREVIOUS 
MISCARRIAGES 
MEDIAN (IQR) 
 
3 (3-4) 
 
4 (3-6) 
 
0.02 
PARITY 
NULLIPAROUS (%) 
 
28 (64) 
 
34 (76) 
 
0.22 
 
Table 5. 1: Demographic data of large retrospective study of 89 women. There was no 
significant difference in maternal age or parity in women who had an ongoing pregnancy 
beyond 10 weeks gestation or a further miscarriage. However, women with a miscarriage 
had more previous miscarriages (p=0.02, Mann-Whitney U test).  
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5.2.2 Assessing uNK and senescent factors in predicting 
pregnancy outcome 
 
As the calculated uNK centile and senescent markers’ density is not from a normal 
distribution, I applied the Mann-Whitney statistical test to investigate an association 
between uNK centile or cell senescence and pregnancy outcome. This statistical test 
investigates whether the distribution of uNK or senescent markers differ in both 
groups of women.  
Statistical significance was reached when p < 0.05. 
In this study, I found that the uNK centile test was not a predictor of subsequent 
pregnancy outcome (p=0.55) (Figure 5.1). The distribution between both groups 
were similar. This supports previous findings in the literature. 
 
 
Figure 5. 1: uNK centile and prediction of pregnancy outcome. There is no difference 
between the uNK centile value in the groups who had a subsequent live birth or ongoing 
pregnancy beyond 10 weeks and the group of women who had a further miscarriage (p= 
0.55; Mann-Whitney U test). 
 
 
uNK centile and outcome 
LB/O M 
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Next, the HMGB2 loss was measured in endometrial stroma, glands and lumen. 
There was no statistically significant difference between women with positive 
pregnancy outcome to those with further miscarriage when assessing cell 
senescence using HMGB2 loss (stromal p value = 0.4, glandular p value = 0.6, luminal 
p value = 0.92). The graphs are presented in Figure 5.2. 
Cell senescence measurement using p16 antibody was more discerning between the 
two groups of women. The density of p16 in endometrial glands and lumen were 
significantly different between women with positive pregnancy outcome and those 
with further miscarriage (p = 0.01; p = 0.04 respectively). In comparison, p16 density 
in the stroma did not discriminate between the two groups of women (p = 0.37). 
This is illustrated in Figure 5.3.  
Work in our research unit analysed p16 IHC staining using a heat-map similar to the 
uNK centile to increase accuracy due to timing of biopsies. The formulated p16 
centile value is the normalised P16 density for day of cycle based on 308 samples 
(Brighton et al., 2017). I converted the p16 density values to centile and repeated 
the statistical analysis discussed in the last paragraph.  
The levels of p16 senescence in the endometrial glands and lumen between the two 
groups of women became more statistically significant, when p16 centile values 
were used instead of p16 density (p = 0.005; p = 0.015 respectively) (Figure 5.3, 5.4).  
The p16 centile in the endometrial stroma still showed no significant difference 
between women who had a positive pregnancy outcome or women with a further 
miscarriage (p = 0.47). 
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Based on these findings, I have excluded the use of HMGB2 in a combined pre-
conceptual endometrial test as the levels were nearly identical in both groups. 
Focussing on p16 centiles, the most statistically significant discriminating factor 
between women with a positive pregnancy outcome and those with further 
miscarriage is glandular p16 centiles. Therefore, I have used the glandular p16 
centiles to investigate logistic regression modelling with the aim to clarify its 
relationship with uNK centiles and pregnancy outcomes. 
 
5.2.3 Regression Modelling to improve uNK test 
 
Logistic regression modelling was used to formulate an equation that describes the 
relationship of uNK and glandular p16 values with pregnancy outcomes. The CD56 
and p16 values were logged to make them a linear co-variable.  Whilst the model 
described the outcomes in relation to uNK and glandular p16 values, the number of 
previous miscarriages is by far the largest factor in the model as shown in Table 5.2. 
The regression model also did not indicate that the endometrial test results were 
significant factors after removing the factor of number of previous miscarriages from 
the test equation (Table 5.3).  
 
Table 5. 2: Logistic regression modelling using factors of uNK (CD56) centile, glandular p16 
centile and number of previous miscarriages. 
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Table 5. 3: Logistic regression modelling using factors of uNK (CD56) centile and glandular 
p16 centile only. 
 
The logistic regression model was complicated and clinically, was no improvement 
on asking women how many miscarriages they had.   In addition, the model did not 
make any biological sense.  Hence, I planned a new approach.  Instead of using the 
Log values I went back to using the centile values of uNK and glandular p16, as this 
has a similar effect on making the data more linear. In addition, I used the findings 
of the regression modelling of subtracting the glandular p16 from the uNK cell 
value.   
This enabled me to come up with a simple, clinically usable formula of ‘uNK – 
glandular P16’ centile.  This has biological meaning because it assesses; (i) the 
synchronicity of the stromal and glandular decidualisation process, (ii) CD56 cells 
and their target senescent cells and (iii) stromal/glandular interactions. 
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5.2.4 Endometrial factor synchronicity test 
 
I returned to the hypothesis that synchronicity of endometrial factors in 
decidualisation is paramount to successful pregnancy outcome. uNK cells play a role 
in clearing senescent cells and suggests a balance in the activity of uNK cells and 
presence of cell senescence is required to support pregnancy (Brighton et al., 2017). 
Furthermore, uNK cell activity in the stroma and glandular maturation or 
differentiation appears to improve prediction of subsequent pregnancy as seen in 
previous work using Noyes criteria in histological dating (Liu et al., 2014).  
Hence, a test that combines stromal and glandular development is likely to assess 
the synchronicity of the various compartments in the endometrial preparation for 
pregnancy. We hypothesise that disruption of this process would lead to impaired 
decidualisation. Here, I used uNK (CD56) centiles as a surrogate marker for stromal 
development and glandular p16 centiles for glandular development. Therefore, I 
designed the formula of ‘uNK minus glandular p16’ centile test to assess this 
synchronicity.  
Results are expressed as [median ‘difference value’ (Q1-Q3)]. The results show that 
a larger positive value of difference between uNK and glandular p16 centiles is 
associated with further miscarriage (13 (-14 to 39.3)) as compared to in women who 
had a live birth (-11 (-35.3 to 15.1)) (Figure 5.5). This difference in medians is 
significant using Mann-Whitney test (p=0.016). The significance is further supported 
by narrow inter-quartile ranges. This would suggest high uNK cell density that 
exceeds the predicted level of senescence is more prevalent in subsequent poor 
pregnancy outcome. Based on these findings, we would be able to set a cut off 
‘difference value’ of 13. In this study, a value of ≤ 13 reflects 75% of live births or 
ongoing pregnancies beyond 10 weeks gestation and 50% of women with a further 
miscarriage. This cut off point is demonstrated by the red line in Figure 5.5. 
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Synchronicity in endometrial preparation for pregnancy 
 
Figure 5. 5: Comparison of ‘uNK minus glandular p16’ centile value and pregnancy 
outcome. There is a significant difference between the 2 groups of women and the 
confidence intervals are narrow (p=0.0163). The cut-off value of 13 denoted by the red line 
in this graph, could potentially be used to predict live birth rate in a subsequent pregnancy.  
 
 
 
 
 
 
 
 
 
 
LB/O M 
uNK minus glandular p16 
121 
 
 
The histogram below is a pictorial depiction of the results demonstrated in Figure 
5.5. It illustrates a shift of ‘difference values’ to the right of 0, in women who have 
a further miscarriage. This means that uNK centile values are generally higher than 
glandular p16 centiles in women with a further miscarriage. 
 
 
Figure 5. 6: Histogram showing distribution of ‘uNK – glandular p16 centile’. The blue bars 
and line represent women with a live birth or pregnancy beyond 10 weeks gestation (LB/O) 
and, the striped bars and red line represent women with a further miscarriage (M). The 
histogram shows a shift to the right in women with poor pregnancy outcome. These 
women appear to have proportionately higher uNK centiles to glandular p16 centiles. 
 
 
 
 
 
 
Value of difference (uNK – glandular p16) 
LB/O 
M 
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5.2.5 Validity of uNK – glandular p16 centile test 
 
To test the validity in outcome prediction of ‘uNK – glandular p16’ centile test, I 
performed a receiver operating characteristic (ROC) analysis.  
The accuracy of a test depends on how well the test separates the group being 
tested into those with and without the disease in question. Accuracy is measured by 
the area under the ROC curve. An area of 1 represents a perfect test. An area of 0.5 
represents a test that is unable to differentiate between the two groups and is no 
better than chance. The traditional academic point system for the accuracy of a 
diagnostic test is as below (Tape, Thomas G. The Area Under an AUC Curve. 
University of Nebraska Medical Center. http://gim.unmc.edu/dxtests/Default.htm):  
 
 
 
 
 
 
 
 
Figure 5. 7: Concept of area under curve in receiver operating characteristics. The ROC 
curve assesses the sensitivity and specificity of a test and determines the robustness of a 
test. An excellent test is a test that has a high true positive rate and a low false positive 
rate. 
 
 
 
 
Area under the curve value 
explained: 
0.90-1 = excellent test   
0.80-0.90 = good test   
0.70-0.80 = fair test 
0.60-0.70 = poor test 
0.50-0.60 = failed test 
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In this study, I have shown the ability to predict a further miscarriage is improved in 
area under the curve from 54% using uNK centile alone to 65% with ‘uNK – glandular 
p16’ centile test (Figure 5.8). The AUC value suggests that although better, the ‘uNK 
– glandular p16’ test has a poor ability as a predictive test. Clinically, the ‘uNK – 
glandular p16’ centile test is not yet robust to reliably predict pregnancy outcome. 
However, it may identify women who would benefit from further intervention or 
therapy. In the setting of future research in endometrial factor of recurrent 
reproductive failure, the test may help focus on a target population with 
interruption to synchronicity between uNK cells and glandular cell senescence. 
 
 
Figure 5. 8: ROC curve showing ability of two tests; i) uNK centile test and ii) ‘uNK – 
glandular p16’ centile test, in predicting a further miscarriage. The AUC for the uNK centile 
test and ‘uNK-glandular p16’ centile test was 0.54 and 0.65 respectively. 
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In order to determine the significance of the difference between the two ROC 
curve analyses, I compared the two AUC values of the uNK centile and ‘uNK – 
glandular p16’ centile test using Hanley & McNeil statistical formula. The table 
below shows that the improvement seen in predictive ability of ‘uNK – glandular 
p16’ centile test is significant with p value 0.011. 
 
Table 5. 4: Hanley & McNeil statistical test; this statistical test compares two AUC values to 
determine whether there is a significant difference between two tests in its ability to 
predict outcome. The ‘uNK – glandular p16’ centile test is an improved predictive test 
compared to uNK centile test with a significant p value of 0.011. 
 
5.3 Discussion 
5.3.1 Endometrial stromal and glandular cell synchronicity 
 
To elucidate whether uNK cell density and glandular cell senescence change 
together in the endometrium to encourage implantation, I designed a test formula 
of ‘uNK – glandular p16’ centile test. This was extracted from conclusions of the large 
test development study which showed an association between glandular p16 centile 
and improved pregnancy outcomes. This formula was analysed for all 89 women 
from the test development study. The value was plotted for each patient and divided 
into two defined groups. The groups were women with subsequent first trimester 
miscarriage and women with subsequent ongoing pregnancy beyond 10 weeks’ 
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gestation or live birth. The difference between uNK and glandular cell senescent 
activity was compared in the two groups. 
The loss of synchronicity denoted by higher values of uNK cells in comparison to 
glandular senescence was found to be more prevalent in women with a further 
miscarriage (Figure 5.5 and Figure 5.6). This could describe an overactivity of uNK 
cells or delayed glandular development leading to impaired decidualisation. A 
threshold value of 13 depicts the difference value point at which below it, identifies 
75% of women with ongoing pregnancy or live birth and 50% of women who have a 
further miscarriage. I aim to use this threshold in a prospective RCT setting to 
evaluate this combined pre-conceptual endometrial test of endometrial stroma and 
gland development (uNK – glandular p16 centile test). 
The limitations of this combined test are apparent in the ROC curve presented in the 
results. It shows that the ‘uNK – glandular p16’ centile test improves prediction over 
uNK test alone. However, with an area under the curve of 0.65, the combined test is 
still poor in differentiating women with a good pregnancy outcome to those with a 
further first trimester miscarriage. The limitations are caused by miscarriage of 
karyotypically abnormal embryos, the unknown effect of an endometrial biopsy and 
variation between menstrual cycles (inter-cycle variation). These factors may also 
prevent any pre-conceptual endometrial test from achieving excellent predictive 
ability. Therefore, it is possible that the best we can expect to achieve is marginal 
improvement in prediction of subsequent pregnancy outcomes. However, the 
improvement may still be relevant clinically.  
I will attempt to address these limitations in the next chapter evaluating the 
combined test. 
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Chapter 6: Evaluation of combined test 
6.1 Background 
The combined test ‘uNK – glandular p16’ centile test has been shown to improve 
predictive ability of pregnancy outcome of the uNK test. However, it is not yet a 
robust test for clinical use. In this chapter, I aim to evaluate this test and its 
limitations in a randomised-controlled trial setting to investigate reproducibility and 
address limitations. 
 
6.1.1 Evaluating the combined test 
The hypotheses tested: 
 Synchronicity of endometrial stromal and glandular development are 
important for appropriate decidualisation and endometrial preparation for 
pregnancy. 
 Endometrial stromal development is assessed by uNK cell density based on 
day of menstrual cycle. This hypothesis was made base on the fact that 
stromal cell proliferation followed changes in uNK cell density (Figure 4.6) 
and the role of uNK cells clearing stromal senescent cells, which also 
stimulates stem cells and proliferation (Brighton et al., 2017). 
 Endometrial glandular development is assessed by senescence of glandular 
cells measured by p16. This is due to senescence reflecting the mature state 
of a cell. 
 Higher levels of uNK cell density based on day of cycle compared to glandular 
senescence is more prevalent in women with further miscarriage. This may 
reflect loss of synchronicity of the endometrial stromal and glandular 
compartments leading to pregnancy loss. This could describe an overactivity 
of uNK cells or delayed glandular development leading to impaired 
decidualisation. 
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Limitations to address: 
 Miscarriage of karyotypically abnormal embryo 
 Inter-cycle variation or effect of endometrial biopsy 
 
6.1.2 Methods  
Randomised-controlled trial (RCT) setting 
There is a registered, pilot randomised controlled trial in our unit that is assessing 
the effect of endometrial scratch (biopsy) against ‘sham-procedure’ in recurrent 
miscarriage (Scratch in Miscarriage (SiM) trial). This pilot trial is a fellow research 
student’s research project. I played a role as an investigator on the trial. I helped 
recruit and provide care for women entered into this trial. The trial received ethical 
approval from NHS National Research Ethics 2015 as mentioned in Chapter 2. The 
inclusion criteria for this trial was age 18 to 42 with history of at least two 
miscarriages and currently trying to conceive. It has reached its target of 109 
recruited patients. The recruited patients provided written consent to the trial and 
for research samples to be stored.  
The endometrial samples were taken using the same method as described in 
Chapter 2. Endometrial samples that were obtained in the intervention arm have 
been stored in our research Tissue Bank for future research.  
In order to investigate the reproducibility of the combined test of ‘uNK – glandular 
p16 centiles’ as a predictive test, I retrieved these samples from tissue bank to 
process using IHC as per study protocol. Each patient had a calculated uNK and 
glandular p16 centile. The value of ‘uNK – glandular p16 centiles’ was derived from 
these values. The outcome measure of interest to test the predictive ability of the 
combined test, was the first pregnancy event within 3 menstrual cycles from the 
endometrial biopsy.  
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The patients were divided into groups based on their pregnancy outcome:  
1. Women with a live birth  
2. Women with first trimester miscarriage of karyotypically abnormal embryo 
3. Women with further first trimester miscarriage  
4. Women not achieved pregnancy in the 3 months 
 
I have separated the women who miscarried a karyotypically abnormal embryo into 
their own group because this showed the correct response of the endometrium to 
the conceptus. Therefore, they represent an appropriate endometrial response and 
are distinct from women who miscarry a normal embryo, or where we do not have 
this information. 
The values of uNK and glandular p16 centiles underwent statistical analysis as per 
study protocol in Chapter 5. Using the cut-off value of ≤13, I then divided patients 
into two groups to compare their subsequent pregnancy outcome. Group 1 has a 
‘difference value’ of ≤13 and Group 2 a ‘difference value’ of >13.  
To support the validity and reproducibility of this combined test, a cut-off value of 
13 would be able to discriminate between women more likely to have a live birth to 
those with a poor pregnancy outcome. This will assess the importance of 
endometrial synchronicity between uNK cell density and glandular cell senescence. 
Cytogenetic testing 
During the course of this RCT study, cytogenetic testing was offered to all women 
who had a further miscarriage following current guidelines in recurrent pregnancy 
loss. Appointments were set up by the research team to discuss the results. The test 
may find normal or abnormal karyotype of embryo, and whether parental karyotype 
is advised. This effort was also made to address the study limitation of pregnancy 
loss attributable to karyotypically abnormal embryos, which hinders many research 
studies involving recurrent pregnancy loss. 
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6.2 Results 
6.2.1 SiM trial and limitations 
 
In the SiM trial, 55 patients were randomly allocated to the intervention arm. In the 
intervention arm, women underwent an endometrial scratch with a Wallach 
endometrial sampler in the mid-luteal phase of the menstrual cycle and advised to 
try to conceive from the next menstrual cycle.  The primary outcome for my project, 
was assessed as the first pregnancy achieved or not within the first three months 
after the intervention as any positive effect of the biopsy on the endometrium was 
thought to last 3 months. We also believe that after 3 months the endometrial 
sample is not likely to reflect the endometrium at the time of implantation. 
In this study sample (n=55), 31 women conceived within 3 months and 24 did not. 
This meant a large proportion could not be analysed for pregnancy outcome (44%). 
The trial was designed to obtain biopsy from women with recurrent miscarriage and 
collect pregnancy outcome prospectively.  It was hypothesised that most women 
would conceive within the 3 months of the biopsy because women with recurrent 
miscarriage would have a highly receptive endometrium. However, this was not 
reflected in the results of the trial. The problem with the trial was loss of 34 women 
because they conceived before recruitment or randomisation to the endometrial 
scratch procedure. This group of women are likely to represent the superfertile 
women with highly receptive endometrium. The inability to recruit these women 
may explain to a degree, the proportion of women who did not conceive within the 
3-month period. Please refer to the consort diagram in Figure 6.1 for illustration. 
 
 
131 
 
 
Figure 6. 1: CONSORT diagram for the SiM trial (unpublished). Reproduced with permission 
from Dr V Kandavel and Prof S Quenby (Biomedical research unit- UHCW/University of 
Warwick). In the process of recruiting and randomising women into the trial, 34 women 
were excluded due to being pregnant before we were able to recruit or randomise them.  
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6.2.2 Demographics 
In this study sample of 55 women, two were excluded from analysis as the first had 
a pregnancy of unknown location and the second was pregnant at time of biopsy, 
then proceeded to have a live birth. In the remaining 53 women, 18 had a live birth, 
11 miscarried and 24 did not conceive in the time period for my study. Among the 
women who miscarried, 2 were found to have miscarried trisomy pregnancies 
(Trisomy 16, 22). The demographics of these women can be found in Table 6.1. There 
was significant difference between age of women with live birth or miscarriage and 
women who did not conceive within 3 months or had a karyotypically abnormal 
embryo (Kruskal-Wallis; p=<0.0001). However, there was no difference in number 
of previous miscarriages and parity between the groups (Kruskal-Wallis; p=0.59 and 
Chi-square; p=0.32 respectively). 
 
 Live birth 
 
N=18 
Miscarriage 
 
N=9 
Miscarried 
trisomy 
N=2 
Did not 
conceive in 3 
months 
N=24 
Age; mean  
(SD) 
31 
(4.1) 
28 
(4.3) 
36 
(0.7) 
36 
(4.5) 
No previous 
miscarriages 
Median (IQR) 
3 
(2-3) 
3 
(3-3) 
2 
(2-2) 
3 
(2-5) 
Nulliparous N 
 (%) 
10 
(56%) 
7 
(78%) 
1 
(50%) 
10 
(42%) 
 
Table 6. 1: Demographic details of women who underwent an endometrial biopsy in the 
mid-luteal phase of a menstrual cycle. There appeared to be a significant difference in 
maternal age in this demographic. The women who miscarried a trisomy pregnancy or did 
not conceive within 3 months of their endometrial biopsy, were older. There was no 
difference in number of previous miscarriages or parity. (Kruskal-Wallis test) 
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6.2.3 Test validation 
 
I have used the same study protocol (Chapter 5) to investigate the distribution of 
uNK centile and glandular cell senescence with pregnancy outcome in the women 
identified in the RCT setting.  The trial was designed to obtain a biopsy from women 
with recurrent miscarriage and collect pregnancy outcome prospectively.  My aim 
was to investigate whether the ‘uNK-glandular p16’ centile test could predict 
subsequent pregnancy outcome by assessing endometrial stroma and glandular 
synchronicity. I applied the Kruskal-Wallis and Mann Whitney test to assess this 
association. 
In Figure 6.2A, there was significant difference of uNK centile values between the 4 
groups (Kruskal-Wallis; p=0.02). uNK centiles appear to most significantly 
discriminate women who will have a live birth to women who did not conceive 
within 3 months (Mann-Whitney; p=0.012). Women who did not conceive within the 
3 months had higher uNK centile values with a median of 44th centile compared to a 
median of 18th centile in women with a live birth. However, the uNK centile values 
were similar in the women who had a miscarriage to those who did not conceive 
within 3 months (Mann-Whitney; p=0.74). 
Glandular p16 centile did not show significant difference across all four groups 
(Kruskal-Wallis; p=0.28). However, unlike the uNK centile, glandular p16 centile was 
able to discriminate between women who had a miscarriage and those who did not 
conceive within 3 months (Mann-Whitney; p=0.029). This is illustrated in Figure 
6.2B. 
Combining the ability of both tests using ‘uNK – glandular p16’ showed that the 
combined test is able to predict pregnancy outcome and confirms findings in 
Chapter 5. There is a significant difference in ‘uNK-glandular p16’ centile values 
between women who had a live birth and women who had a further first trimester 
miscarriage (Mann-Whitney; p=0.036) (Figure 6.3). 
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Using the ‘uNK-glandular p16’ cut-off value of ≤ 13 as described in Chapter 5, I 
divided the study’s participants (n=53) into two groups to compare their subsequent 
pregnancy outcome. Group 1 had a ‘difference value’ of ≤13 (n=30) and Group 2 a 
‘difference value’ of >13 (n=23). In Group 1, I was able to predict a live birth rate of 
43% (13/30) in the 3 months cycle; compared to live birth rate of 22% (5/23) in 
Group 2. Furthermore, a ‘difference value’ > 13, predicted 8 out of 9 miscarriages 
not affected by known trisomy. 
According to the hypothesis derived in Chapter 5, a ‘uNK – glandular p16’ centile 
value of ≤13 would have identified women with an endometrium that was within 
normal limits and preparing effectively for pregnancy. Interestingly, the uNK-
glandular p16 test also correctly predicted both miscarriages of abnormal karyotype 
(difference value ≤13) and all 3 karyotypically normal embryos (difference value 
>13). However, the numbers are too small to make any conclusions.   
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Figure 6. 2: uNK centile and glandular p16 centile in the outcome groups; (i) women with a 
live birth, (ii) women with a trisomy pregnancy loss, (iii) women with a further miscarriage 
and (iv) women who did not conceive in the specified timeframe.  
Graph A demonstrates that there was significantly higher uNK centile value in women who 
did not conceive when compared to women with a live birth (p= 0.012; Mann-Whitney U 
test). Graph B illustrates that there was significantly less glandular p16 expression in 
women who miscarried compared to those who did not conceive (p= 0.029; Mann-Whitney 
U test). 
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Figure 6. 3: The ‘uNK – glandular p16’ centile test and SiM trial outcome groups. The 
combined test did predict women who miscarried from the women who conceived in the 3-
month period. The test was significantly different in women who miscarried and women 
who had a live birth (p= 0.036; Mann-Whitney U test). The red line depicts the ‘difference 
value’ of 13, which was determined as a useful cut-off value in Chapter 5. A ‘uNK – 
glandular p16’ centile test value of ≤ 13, predicted a live birth rate of 43% (13/30) within 
the 3-month period. This is compared to a live birth rate of 22% (5/23) with a value of >13. 
All but one woman in the miscarriage group had a value above 13. 
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6.3 Discussion 
6.3.1 ‘uNK – glandular p16’ centile test 
The evaluation of the combined pre-conceptual endometrial test (‘uNK – glandular 
p16’ centile test) showed that it was reproducible in the context of the pilot ‘Scratch 
in Miscarriage’ RCT study conducted in our research unit. The SiM trial aim is to 
assess the effect of endometrial scratch (biopsy) against ‘sham-procedure’ in 
recurrent miscarriage. We chose to evaluate the combined test on women in the 
intervention arm of this trial to reduce bias; as it was a prospective study, had strict 
inclusion criteria and the participants were not offered any other therapy.  
Only 29 of the 53 participants had a pregnancy event within 3 months of their biopsy. 
The 29 women were divided into groups based on their pregnancy outcome. The 
first group had a live birth (n=18). The second group had a miscarriage of a trisomy 
fetus (n=2) and therefore were put in a separate group because miscarriage of 
trisomy pregnancies is considered normal. The third group had a further first 
trimester miscarriage (n=9). Of the third group 3 women miscarried karyotypically 
normal embryos and we were unable to obtain karyotyping for the other 6 women.  
The statistical analysis showed a difference between those that miscarried and those 
that had a live birth. Therefore, we have been able to validate the ‘uNK – glandular 
p16’ centile test with pregnancy outcomes conceived within 3 months.  The period 
of 3 months was our pre-specified outcome measure from the SiM trial. I did re-
analyse the data with one year’s follow up and there was no difference in the ‘uNK-
glandular p16’ centile test between the two groups. The problem was that some 
who miscarried in the first pregnancy after the biopsy conceived again quickly and 
had a live birth. This is a good outcome for the patients and clinical trial perspective 
but is less useful in our understanding of the endometrium. In addition, some 
women conceived more than 6 months after the biopsy and it is unlikely the test 
performed would reflect the process of implantation for these women. 
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Limitations of this evaluation study 
One of the limitations of the evaluation study is the small numbers that were studied 
as 24 women did not conceive in the 3 months following their biopsy. The range of 
uNK centile and glandular p16 centile values were large and overlapped affecting 
the accuracy of the test (Figure 6.2). We also aimed to test all further miscarriage 
with cytogenetics. However, we found testing for cytogenetics on further pregnancy 
loss was not straightforward. Only 5 of 11 miscarriages had a cytogenetic result due 
to reasons of insufficient or no pregnancy tissue obtained.  
Another aspect that will be explored next, is the presence of inter-cycle variation. 
We know that the endometrium rejuvenates each menstrual cycle. This invokes the 
question of whether this ultimately limits the pregnancy outcome predictive ability 
of a static test, which evaluates endometrial preparation for pregnancy in only one 
menstrual cycle. Hence, limiting the value of this combined test for pregnancies 
conceived beyond the 3-month period as discussed above. 
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INTER-CYCLE VARIATION  
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Chapter 7: Inter-cycle Variation 
 
In our research team, information from repeat biopsies from the same patient, have 
been analysed to investigate inter-cycle variation in uNK centile values. Some 
patients have shown a change in response to an endometrial biopsy, while others 
do not.  
I extracted data from the repeat biopsies for a 3-year retrospective study (2014 – 
2017) of women with recurrent reproductive failure, who had repeat biopsies within 
a 6-month duration and had a subsequent pregnancy outcome within a year of the 
second biopsy. This study of 60 women with recurrent reproductive failure, were 
divided into two groups. Group 1 had a subsequent ongoing pregnancy beyond 12 
weeks’ gestation and Group 2 had a further first trimester miscarriage. The aim was 
to investigate uNK centile variation between cycles and association to pregnancy 
outcomes. 
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7.1 Results 
 
Table 7.1 shows the demographic details of this study. There is no significant 
difference in the characteristics of the women in both groups. The mean age is 35.7 
years and mean BMI is 23.9 for the whole study sample of 60 women. More women 
had infertility issues 56.7% and most were nulliparous 75%. The majority of women 
had an interval between biopsy of ≤ 3 months (80%). The median number of embryo 
transfers for the infertility patients was 4 (IQR: 2-7) and median number of previous 
miscarriages for women with recurrent pregnancy loss was 5 (IQR: 3-7). 
 
 
Table 7. 1: Demographic data of women with repeat biopsies and a pregnancy event within 
1 year of second biopsy (n=60). There was no significant difference in the two groups in all 
the demographic data above; maternal age, BMI, fertility, parity and interval between 
biopsy. Most women were nulliparous (75%) and had an interval between biopsy within 3 
months (80%).  
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The two groups were analysed separately, to investigate uNK cell density changes 
following endometrial tissue injury and whether this relates to subsequent 
pregnancy outcome in women with recurrent reproductive failure. Each patient’s 
biopsy was processed using IHC to calculate a uNK centile value. The first biopsy’s 
uNK centile was compared to that of the paired second biopsy to assess inter-cycle 
variation for each group. The aim was to assess whether the endometrium behaved 
differently between menstrual cycles in women who had a positive pregnancy 
outcome and those who did not. I used the Wilcoxon statistical test to compare the 
paired biopsies and p <0.05 was significant. Results are reported as (Median 
difference (95% CI); p value). 
The results showed that women with a subsequent pregnancy beyond 12 weeks had 
a significant fall in their uNK centile value in the second biopsy (-13 (-26.7 to -4.6); p 
= 0.0073). In comparison, the uNK centile values did not change significantly in 
women with a further IVF failure or miscarriage (-1.5 (-16.6 to 10.8); p = 0.585). This 
is illustrated in Figure 7.1. 
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7.2: Advantages and limitations 
 
This study is one of the first examining repeat endometrial biopsies and subsequent 
pregnancy outcomes in reference to uNK cell activity. It provides insight into the 
difference in the decidual process between menstrual cycles and raises two theories. 
The first is the concept that the repeat samples show the variation present in 
menstrual cycles as the endometrium undergoes regeneration and adaption as a 
crucial role in human reproductive success. The second theory is that the 
endometrial biopsy is a source of endometrial injury and the difference in uNK 
centile values found are a direct reflection of the biopsy. Therefore, the difference 
recorded is the ability of the endometrium to respond to the stimuli and not just a 
passive reflection of decidual processes.  
Another advantage of this study is the enrichment of its study population. As 
previously stated, the median number of embryo transfers for the infertility patients 
was 4 (IQR: 2-7) and median number of previous miscarriages for women with 
recurrent pregnancy loss was 5 (IQR: 3-7). This reflects a more severe phenotype, 
which confers a higher likelihood of aberrant decidualisation and hence is more 
demonstrable when studied.  
The limitation of this study is the bias introduced as a retrospective study, which 
includes data collection bias. This type of study can be run efficiently in this setting 
because it is less time-consuming and is low cost. Due to the proportion of women 
who do not conceive and are loss to follow up following an intervention, as seen in 
the prospective RCT study (SiM trial), the number that would need to be entered 
into a prospective cohort study would be large. 
This study is also limited by the unknown proportion of miscarriages or implantation 
failures which will be due to embryo factors. Furthermore, due to the very nature of 
variation between menstrual cycles, it is difficult to determine the duration in which 
the results would still be reflective of the patient’s endometrial status and the 
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optimum time between repeat endometrial biopsies. The more commonly accepted 
time-frame that would still reflect endometrial status, is a conception event within 
3 months of an endometrial biopsy test. 
Another factor to be considered, is the results of this study are still not yet robust as 
confidence intervals are wide. 
 
7.3: Impact of study 
 
This is likely the most important finding in my research study as a whole. The results 
give credence to scientific thought that each menstrual cycle must differ as it 
continues to move through its regenerative and adaptive phases (Lucas et al., 2016; 
Lucas et al., 2013). As evidence emerges that uNK cells and senescent cells form part 
of the mechanisms of decidualisation, it is reasonable to suggest that they’re activity 
changes between cycles as the endometrium aims to balance its receptive and 
selective traits, which are important for implantation and reproductive success.  
This study suggests that a reduction in uNK cell density in response to endometrial 
tissue injury (endometrial biopsy) appears to be associated with higher rates of 
ongoing pregnancies beyond 12 weeks gestation. These findings add to current 
evidence that endometrial plasticity (the ability of the endometrium to adapt from 
cycle to cycle in response to stress signals) is paramount to endometrial preparation 
for pregnancy (Lucas et al., 2016).  
 
Concept of endometrial plasticity 
The Warwick group has explored the concept of endometrial plasticity and its 
importance in reproductive fitness. It is hypothesised that reproductive success is 
dependent on a constant homeostatic rebalancing of embryonic and maternal traits 
(Chuong et al., 2013; Crespi & Semeniuk, 2004; Emera et al., 2012). This is 
particularly important due to the invasive nature of human embryos and its intrinsic 
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chromosomal instability. The cyclical regeneration of the endometrium is 
remarkable and is associated with an abundance of adult stem cells, which are 
mainly found around the spiral arteries (Du et al., 2012; Du & Taylor, 2010; Gargett 
et al., 2012; Gargett & Ye, 2012; Lucas et al., 2016). The underlying mechanism for 
recruitment of these mesenchymal stem cells which differentiate into mature 
stromal cells is still unclear but is likely to differ following ‘endometrial injury’; such 
as menstruation, miscarriage or parturition (Lucas et al., 2016). This innate 
adaptability may explain the high rate of successful pregnancy outcome in women 
who suffer from repeated pregnancy loss.  
 
Patient-specific response 
In addition, the patient-specific response to endometrial injury is highlighted in this 
study. It appears that the endometrium behaves differently for women who have a 
subsequent successful pregnancy, in the months preceding conception. This 
variation between patient’s response to the endometrial biopsy likely determines 
the clinical benefit of the scratch procedure. These findings also support the 
limitations of a static test taken in one menstrual cycle in predicting subsequent 
pregnancy outcomes, as it does not assess each patient’s individual endometrial 
response. 
Ideally, the repeat endometrial biopsy test would identify women with an adaptive 
endometrium, who will have a high likelihood of positive pregnancy outcome. 
Conversely, those where this is aberrant would be stratified to having a poorer 
outcome prediction, as their decidualisation process is disordered. If the validity of 
this identification process is confirmed in future research, it may be a measure to 
focus recruitment of women into trials and enable targeted therapies.  
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Future challenge 
The future challenge is to confirm or refute the findings that a fall in uNK cell density 
in response to ‘endometrial injury’ predicts improved subsequent pregnancy 
outcome using larger, prospective cohort studies. It would then be essential to 
understand whether there are specific signature patterns that discriminate women 
who have RPL, are ‘superfertile’ or have RIF. If there is credence to these findings, 
future research would be able to use these signature uNK density changes to focus 
recruitment to trials and target therapies.  
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SUMMARY OF CONCLUSIONS AND 
FUTURE WORK 
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Chapter 8: Summary of conclusions and future 
work 
The overall aim of this research project is to design a pre-conceptual endometrial 
test that can improve prediction of subsequent pregnancy outcome when compared 
to the uNK test in recurrent pregnancy loss. There is a dearth of strong evidence in 
predicting future pregnancy outcomes in couples with recurrent reproductive 
failure. This is due to the highly complex and varied factors that influence the 
outcome of care in these couples. It makes for a difficult clinical situation fraught 
with controversy in its management and causes significant stress for couples. The 
ability to predict outcome and profile or identify women with poorer prognosis will 
help individualise care and focus research more effectively. 
The uNK cell test has been widely adopted because they have consistently been 
found to be higher in reproductive failure (Quenby et al., 1999; Tuckerman et al., 
2007), correlates negatively with markers of decidualisation (Kuroda et al., 2013) 
and been used to identify women who may benefit from steroid therapy to prevent 
repeated pregnancy loss (Tang et al., 2011). To date, efforts to design or improve 
prediction tests include work combining uNK test and histological dating using 
Noyes’ criteria (Liu et al., 2014) and assessing activity of uNK cells by measuring 
released interleukin levels (IL-15, IL-18) (Lédée et al., 2016; Lédée et al., 2017). They 
show limited predictive ability. The number of previous miscarriages or implantation 
failures and maternal age remain factors that outweigh other parameters in 
predicting outcome but are themselves unchangeable. My aim was to translate 
novel high-quality laboratory science into a clinical application to improve prediction 
of pregnancy outcome and highlight therapies by understanding underlying 
pathophysiology in recurrent pregnancy loss. If results were encouraging, future 
work would involve a predictive test for women with recurrent implantation failure.  
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The scientific hypotheses that formed the structure of this research project included: 
1. uNK cell density on its own is not a good predictor of pregnancy outcome 
(Liu et al., 2014)  
2. When uNK cell density is normalised for day of cycle creating the uNK 
centile, its ability in predicting pregnancy outcome improves (Brighton et 
al., 2017) 
3. Histological dating includes assessment of endometrial glandular 
development in decidualisation therefore improves predictive ability of 
uNK test (Liu et al., 2014) 
4. Increased rate of proliferation indicated by Ki67 in uNK cells indicates active 
uNK cells and is associated with recurrent pregnancy loss (Lédée et al., 
2016; Lédée et al., 2017) 
5. Endometrial stromal senescence (HMGB2 loss or p16 presence) promotes 
senescence, impairs decidualisation and is associated with recurrent 
pregnancy loss (Lucas et al., 2016). 
 
In assessing the predictive ability of the uNK test, I have demonstrated that the uNK 
test on its own does not predict pregnancy outcome based on 281 women with 
recurrent reproductive failure (Chapter 3). I did find that there was improvement in 
prediction using uNK centile (uNK cell density normalised for day of cycle) but this 
was still not statistically significant.  In the randomised controlled trial, it was 
interesting that uNK centile did appear to predict which women were slower to 
conceive.   
In my research, I have found a pre-conceptual endometrial test that incorporates 
the endometrial stromal and glandular components (uNK – glandular p16 centile 
test) which demonstrated improved prediction of pregnancy outcome when 
compared to the uNK test (Chapter 5). The improvement is illustrated in the ROC 
curve produced but is not robust and still has poor predictive ability (Figure 5.8). 
These findings showed some promise, as it suggested synchronicity between the 
two compartments reflected an ordered decidualisation process and was important 
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for a successful pregnancy. It supported findings by our research team that 
demonstrated the uNK cells’ role in clearing endometrial senescent cells and 
invoking human endometrial stem cell proliferation (Brighton et al., 2017). 
I have shown a corroboration of the above findings relating to the ‘uNK – glandular 
p16’ centile test’s predictive ability, in the setting of a prospective Randomised-
Controlled Trial (RCT) setting (Chapter 6). A strong conclusion could not be made as 
this was limited by the sample size of 53 women. It was found that the most fertile 
women with recurrent pregnancy loss conceived before randomisation and a 
possibly less severe phenotype was recruited into the trial. In addition, only a small 
proportion of miscarriages had cytogenetic results to limit the confounding factor of 
abnormal embryos. However, this setting provided the best option to limit bias. 
Technically, I have been able to design an endometrial pre-conceptual test, that is 
easy to perform albeit not yet robust. The results in conducting this research have 
strengthened and confirmed hypotheses formed in our research unit concerning the 
underlying pathophysiological processes in recurrent reproductive failure. We have 
shown it is possible to assess stromal and glandular development in the 
endometrium using immunohistochemistry (IHC) staining. The study protocol 
developed enables this process to be performed on a large scale and could be 
adopted in future research work analysing pathophysiology.  
This research has also invoked the question of whether the concept of a one-off 
endometrial test is sufficient to provide prognostic information that is strong enough 
to use in a clinical setting. Alternatively, the ‘uNK – glandular p16’ centile test could 
be used to enter women into a randomised controlled trial and would be far better 
than the uNK test. This is because a value >13 selects nearly all those who miscarry 
(89%) with 22% of live births receiving unnecessary treatment, as seen in the RCT 
setting (Chapter 6). In contrast the uNK centile test at >75th centile would have only 
selected 22% of the miscarriages but suggested 11% of the live births received 
unnecessary treatment. It may be possible to further enrich the study population by 
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incorporating the measure of each participants’ endometrial plasticity denoted by 
inter-cycle variation (Chapter 7). 
This combined endometrial pre-conceptual test still requires a significant amount of 
scientific exploration and should only be performed in a research setting. 
 
8.1 Advantages and limitations of this research study 
The advantage of this research project is its systematic approach to investigating the 
predictive ability of a combined pre-conceptual endometrial test. This enabled me 
to assess effectiveness of the uNK cell test as a predictor of pregnancy outcome, 
develop IHC protocol for cell proliferation and cell senescence in specific localised 
areas within the endometrium (stromal, glandular and luminal), describe possible 
relationship between these markers and pregnancy outcome, and evaluate the 
developed combined pre-conceptual endometrial test in a prospective RCT setting. 
I was able to source data from an established ‘Implantation Clinic’ where women 
with recurrent reproductive failure attend for consultation and are offered the uNK 
test. This enabled me to derive information and knowledge from a considerable 
number of couples with more severe phenotype as a population, due to this centre 
being a tertiary referral unit.  
Working closely with our research team examining scientific evidence and 
hypotheses of endometrial factor in recurrent reproductive failure has ensured my 
research project remained relevant to emerging concepts and evidence. It has given 
me insight into how research moves forward and increased my understanding on 
the subject. 
There are limitations to my research project. These can be divided into data 
collection, inherent error in the uNK or IHC test, miscarriage of abnormal karyotype 
embryos and inter-cycle variation.  
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Data collection in the early stages of my research project assessing the uNK cell 
density test (Chapter 3) included retrospective data that would introduce bias. There 
was also bias in recording patient’s pregnancy outcome due to patient self-reporting 
and practice of discharging patients from the ‘Implantation Clinic’ following a 10 to 
12 weeks’ gestation early pregnancy scan. In an ideal situation, live birth instead of 
ongoing pregnancy beyond 10 to 12 weeks’ gestation would be the main outcome 
measure. We were able to mitigate this in the final evaluation test in the prospective 
RCT setting, as all final pregnancy outcomes were known (Chapter 6). 
The combined endometrial test developed (‘uNK – glandular p16’ centile test) was 
based on IHC protocols used for many years in uNK testing. The inherent test errors 
include inter-observer error of 20% as seen in our laboratory and possible error in 
patient reported ovulation test ± 48 hours. This would affect calculated centile 
values for both markers. 
Another limitation to any recurrent pregnancy loss study, is the proportion of first 
trimester miscarriages due to abnormal embryo karyotype. We attempted to 
address this limitation in the final evaluation test, by offering cytogenetics testing 
for all first trimester miscarriages. Despite our best efforts, we managed to gain 
cytogenetic results of only 5 out of 11 first trimester miscarriages in the final 
evaluation test (Chapter 6). This highlights the difficulties in obtaining this 
information for future studies. 
In developing this combined endometrial predictive test, it has revealed the 
presence and importance of inter-cycle variation. It has been shown that women’s 
endometrium reacts differently to endometrial injury (endometrial scratch). Some 
women’s uNK cell levels differ between menstrual cycles and others stay at very 
similar levels. It appears that women whose uNK cell levels fall have more positive 
pregnancy outcomes (Chapter 6). Therefore, it suggests a one-off, static endometrial 
test may not be sufficient to predict pregnancy outcomes as it does not consider the 
variation between cycles. 
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8.2 Future work 
An important area that needs further research is endometrial plasticity, which is the 
ability of the endometrium to respond to stressful stimuli. Understanding how the 
endometrium rejuvenates and how it varies between menstrual cycles, may be key 
to developing a test with a more robust ability to predict pregnancy outcome in 
recurrent reproductive failure. 
This could take the form of repeat biopsies measuring changes in uNK cell or 
senescent markers; which could identify women with poorer prognosis. Research 
could focus on these women with the aim of identifying appropriate, individualised 
therapies. On the other hand, a marker of stem cell response that is important in 
endometrial rejuvenation, could be investigated and developed into a prognostic 
test. 
Another area that I have not explored is the development of angiogenesis and spiral 
arteries during decidualisation. If a relationship between spiral artery development 
and pregnancy outcome can be established, it may further improve our combined 
pre-conceptual test (uNK – glandular p16 centile test) by including a vascular 
component. This would then measure the synchronicity between the stromal, 
glandular and vascular components of the endometrium.    
There is also the question of how the endometrium of women with recurrent 
implantation failure differs from women with recurrent pregnancy loss. Do these 
clinical presentations sit on opposite sides of a clinical scale? The first having an 
excessively selective endometrium and the latter an excessively receptive 
endometrium. Would any future predictive test, work in the same way for both 
presentations? 
Crucially, the recurring theme for any future research into pregnancy outcome for 
couples with recurrent reproductive failure has been the quality of pregnancy 
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outcome data and proportion of miscarriages due to abnormal embryo karyotype. 
It is accepted that the measures needed to address these issues are complex, time-
consuming and carry costs. However, to have meaningful results it is essential. A 
comprehensive database to collect such information has been set up by my 
supervisor and will greatly improve our resources for excellent research. I would also 
suggest that research investigating pathophysiology of endometrial factor or 
designing a test should begin in women with more severe phenotype (≥ 5 previous 
miscarriage or ≥ 3 failed IVF/ICSI) to identify the abnormal processes. This is because 
results may be diluted by data from less severe phenotype which may represent 
chance or embryo abnormality instead of endometrial pathology. Once these 
processes are identified, we would need a way to identify affected women earlier in 
their reproductive history to implement measures and avoid preventable 
miscarriages. 
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